Bio-Techne (TECH) 10-K 25 Aug 21 2021 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Jun. 30, 2021	Aug. 20, 2021	Dec. 31, 2020
Document Information [Line Items]
Entity Central Index Key	0000842023
Entity Registrant Name	BIO-TECHNE Corp
Amendment Flag	false
Current Fiscal Year End Date	--06-30
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021
Document Type	10-K
Document Annual Report	true
Document Period End Date	Jun. 30, 2021
Document Transition Report	false
Entity File Number	0-17272
Entity Incorporation, State or Country Code	MN
Entity Tax Identification Number	41-1427402
Entity Address, Address Line One	614 McKinley Place N.E.
Entity Address, City or Town	Minneapolis
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55413
City Area Code	612
Local Phone Number	379-8854
Title of 12(b) Security	Common Stock, $0.01 par value
Trading Symbol	TECH
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 12,400,000,000
Entity Common Stock, Shares Outstanding		39,079,539
ICFR Auditor Attestation Flag	true

Consolidated Statements of Earn

Consolidated Statements of Earnings and Comprehensive Income - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Net sales	$ 931,032	$ 738,691	$ 714,006
Cost of sales	298,182	255,497	240,515
Gross margin	632,850	483,194	473,491
Operating expenses:
Selling, general and administrative	324,951	260,583	264,359
Research and development	70,603	65,192	62,413
Total operating expenses	395,554	325,775	326,772
Operating income	237,296	157,419	146,719
Other income (expense):
Interest expense	(13,952)	(19,197)	(21,705)
Interest income	473	605	569
Other non-operating income (expense), net	(75,642)	137,650	(13,568)
Total other income (expense), net	(89,121)	119,058	(34,704)
Earnings before income taxes	148,175	276,477	112,015
Income taxes (benefit)	8,590	47,181	15,943
Net earnings, including noncontrolling interest	139,585	229,296	96,072
Net earnings (loss) attributable to noncontrolling interest	(825)	0	0
Net earnings attributable to Bio-Techne	140,410	229,296	96,072
Other comprehensive income (loss):
Foreign currency translation adjustments	32,951	(9,963)	(4,487)
Unrealized gains (losses) on derivative instruments - cash flow hedges, net of tax amounts disclosed in Note 8.	7,060	(3,715)	(9,537)
Other comprehensive income (loss)	40,011	(13,678)	(14,024)
Other comprehensive income (loss) attributable to noncontrolling interest	103	0	0
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent, Total	39,908	(13,678)	(14,024)
Comprehensive income attributable to Bio-Techne	$ 180,318	$ 215,618	$ 82,048
Earnings per share:
Basic (in dollars per share)	$ 3.62	$ 6	$ 2.54
Diluted (in dollars per share)	$ 3.47	$ 5.82	$ 2.47
Weighted average common shares outstanding:
Basic (in shares)	38,747	38,201	37,781
Diluted (in shares)	40,483	39,401	38,892

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2021		Jun. 30, 2020
Current assets:
Cash and cash equivalents	$ 199,091		$ 146,625
Short-term available-for-sale investments	32,463		124,268
Accounts receivable, less allowance for doubtful accounts of $1,229 and $775, respectively	145,385		122,534
Inventories	116,748		103,152
Other current assets	16,919		24,341
Total current assets	510,606		520,920
Property and equipment, net	207,907		176,829
Right of use asset	73,834	[1]	71,465
Goodwill	843,067		728,308
Intangible assets, net	615,968		516,545
Other assets	11,575		13,522
Total assets	2,262,957		2,027,589
Current liabilities:
Trade accounts payable	29,384		23,090
Salaries, wages and related accruals	51,294		31,087
Accrued expenses	15,282		9,093
Contract liabilities	18,995		13,049
Income taxes payable	5,336		2,376
Operating lease liabilities - current	11,602	[1]	9,535
Contingent consideration payable	4,000		5,938
Current portion of long-term debt obligations	12,500		12,500
Other current liabilities	3,891		0
Total current liabilities	152,284		106,668
Deferred income taxes	93,125		101,090
Long-term debt obligations	328,827		344,243
Long-term contingent consideration payable	25,400		199
Operating lease liabilities	67,625	[1]	67,248
Other long-term liabilities	24,462		26,949
Bio-Techne's shareholders' equity:
Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding	0		0
Common stock, par value $.01 a share; authorized 100,000,000 shares; issued and outstanding 38,955,484 and 38,453,046 shares, respectively	390		385
Additional paid-in capital	534,411		420,536
Retained earnings	1,085,461		1,057,470
Accumulated other comprehensive loss	(57,291)		(97,199)
Total Bio-Techne shareholders' equity	1,562,971		1,381,192
Noncontrolling interest	8,263		0
Total shareholders' equity	1,571,234		1,381,192
Total liabilities and shareholders’ equity	$ 2,262,957		$ 2,027,589
[1]	The right of use asset, current operating lease liabilities, and noncurrent lease liabilities on the Consolidated Balance Sheet exclude a definitive agreement entered into by the Company in June 2021 for a 25,000 square foot facility in Dublin, Ireland for the next 25 years with annual rental impact of $0.3 million. The lease will commence during fiscal 2022 after construction is completed by the landlord. As the lease has not commenced as of June 30, 2021, the related asset and liability were not recorded.

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Jun. 30, 2021	Jun. 30, 2020
Accounts receivable, allowance for doubtful accounts	$ 1,229	$ 775
Undesignated capital stock, no par (in dollars per share)	$ 0	$ 0
Undesignated capital stock, shares authorized (in shares)	5,000,000	5,000,000
Undesignated capital stock, shares issued (in shares)	0	0
Undesignated capital stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	38,955,484	38,453,046
Common stock, shares outstanding (in shares)	38,955,484	38,453,046

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity - USD ($) $ in Thousands	Cumulative Effect, Period of Adoption, Adjustment [Member]Common Stock [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]Additional Paid-in Capital [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]Retained Earnings [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]AOCI Attributable to Parent [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]Noncontrolling Interest [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Noncontrolling Interest [Member]	Total
Balances (in shares) at Jun. 30, 2018							37,608,000
Balances at Jun. 30, 2018			$ 25,276	$ (24,682)		$ 594	$ 376	$ 246,568	$ 876,931	$ (44,814)	$ 0	$ 1,079,061
Net earnings									96,072			96,072
Other comprehensive income (loss)										(14,024)		(14,024)
Share repurchases (in shares)							(95,000)
Share repurchases							$ (1)		(15,404)			$ (15,405)
Common stock issued for exercise of options (in shares)							382,000					383,000
Common stock issued for exercise of options							$ 4	36,272				$ 36,276
Common stock issued for restricted stock awards (in shares)							29,000
Common stock issued for restricted stock awards							$ 0		(2,575)			(2,575)
Cash dividends									(48,366)			(48,364)
Stock-based compensation expense								31,775				31,775
Common stock issued to employee stock purchase plan (in shares)							10,000
Common stock issued to employee stock purchase plan							$ 0	1,676				1,676
Employee stock purchase plan expense								505				505
Balances (in shares) at Jun. 30, 2019							37,934,000
Balances at Jun. 30, 2019			(879)			(879)	$ 379	316,797	931,934	(83,521)	0	1,165,589
Net earnings									229,296			229,296
Other comprehensive income (loss)										(13,678)		$ (13,678)
Share repurchases (in shares)							(279,000)					(279,381)
Share repurchases							$ (3)		(50,109)			$ (50,112)
Common stock issued for exercise of options (in shares)							730,000					743,000
Common stock issued for exercise of options							$ 7	69,461	(1,642)			$ 67,826
Common stock issued for restricted stock awards (in shares)							56,000
Common stock issued for restricted stock awards							$ 1	(1)	(2,229)			(2,228)
Cash dividends									(48,902)			(48,902)
Stock-based compensation expense								31,932				31,932
Common stock issued to employee stock purchase plan (in shares)							14,000
Common stock issued to employee stock purchase plan							$ 0	2,312				2,312
Employee stock purchase plan expense								435				435
Surrender and retirement of stock to exercise option (in shares)							(2,000)
Surrender and retirement of stock to exercise option							$ 0	(400)				$ (400)
Balances (in shares) at Jun. 30, 2020							38,453,000					38,453,046
Balances at Jun. 30, 2020			$ (276)			$ (276)	$ 385	420,536	1,057,470	(97,199)	0	$ 1,381,192
Net earnings									140,410		(825)	139,585
Other comprehensive income (loss)										39,908	103	$ 40,011
Share repurchases (in shares)							(120,000)					(120,000)
Share repurchases							$ (1)		(43,177)			$ (43,178)
Common stock issued for exercise of options (in shares)							573,000					627,000
Common stock issued for exercise of options							$ 6	62,102	(12,287)			$ 49,821
Common stock issued for restricted stock awards (in shares)							38,000
Common stock issued for restricted stock awards							$ 0	0	(7,057)			(7,057)
Cash dividends									(49,622)			(49,622)
Stock-based compensation expense								48,065				48,065
Common stock issued to employee stock purchase plan (in shares)							11,000
Common stock issued to employee stock purchase plan							$ 0	2,791				2,791
Employee stock purchase plan expense								917				917
Non-controlling interest in Eminence											8,985	$ 8,985
Balances (in shares) at Jun. 30, 2021							38,955,000					38,955,484
Balances at Jun. 30, 2021							$ 390	$ 534,411	$ 1,085,461	$ (57,291)	$ 8,263	$ 1,571,234

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Cash flows from operating activities:
Net earnings, including non-controlling interest	$ 139,585	$ 229,296	$ 96,072
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization	87,747	82,737	78,171
Costs recognized on sale of acquired inventory	1,565	0	3,739
Deferred income taxes	(27,431)	13,130	(13,582)
Stock-based compensation expense	48,982	32,367	32,280
Fair value adjustment to contingent consideration payable	5,300	(905)	(2,000)
Contingent consideration payments	(337)	(958)	0
(Gain) Loss on investment, net	0	0	(3,702)
Fair value adjustment on available for sale investments	67,879	(137,527)	16,067
Leases, net	75	225	0
Gain on escrow settlement	0	(7,170)	0
Other operating activity	(464)	(732)	2,325
Change in operating assets and liabilities, net of acquisitions:
Trade accounts and other receivables	(15,549)	6,556	(15,000)
Inventories	(7,140)	(14,861)	(13,647)
Prepaid expenses	(1,101)	(2,605)	(698)
Trade accounts payable and accrued expenses	19,091	10,343	6,101
Salaries, wages and related accruals	20,536	2,552	5,013
Income taxes payable	13,426	(7,231)	(9,520)
Net cash provided by operating activities	352,164	205,217	181,619
Cash flows from investing activities:
Proceeds from sale and maturities of available-for-sale investments	66,377	147,120	21,579
Purchase of available-for-sale investments	(39,684)	(70,187)	(43,475)
Additions to property and equipment	(44,301)	(51,744)	(25,411)
Acquisitions, net of cash acquired	(225,352)	0	(289,492)
Investment in unconsolidated entity, net	(556)	1,906	0
Other investing activities	0	0	0
Net cash provided by (used in) investing activities	(243,516)	27,095	(336,799)
Cash flows from financing activities:
Cash dividends	(49,622)	(48,902)	(48,364)
Proceeds from stock option exercises	65,092	70,983	37,950
Re-purchases of common stock	(43,178)	(50,112)	(15,405)
Borrowings under line-of-credit agreement	256,000	40,000	580,000
Payments on line-of-credit	(271,500)	(188,500)	(413,500)
Contingent consideration payments	0	(3,400)	0
Other financing activities	(19,343)	(3,872)	(6,297)
Net cash provided by (used in) financing activities	(62,551)	(183,802)	134,384
Effect of exchange rate changes on cash and cash equivalents	6,369	(2,771)	(308)
Net change in cash and cash equivalents	52,466	45,739	(21,104)
Cash and cash equivalents at beginning of year	146,625	100,886	121,990
Cash and cash equivalents at end of year	$ 199,091	$ 146,625	$ 100,886

Note 1 - Description of Busines

Note 1 - Description of Business and Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Business Description and Accounting Policies [Text Block]	Note 1. Description of Business and Summary of Significant Accounting Policies: Description of business: Use of estimates: Principles of consolidation: one 4 Translation of foreign financial statements: Revenue recognition: ASC 606 Revenue from Contracts with Customers July 1, 2018 606 606 2 ASC 606 Research and development: Advertising costs: 2021, 2020, 2019 Income taxes: not fifty 11 Comprehensive income: not Cash and cash equivalents: three Available-for-sale investments: three six 2018 02, July 1, 2018. Trade accounts receivable and allowances: not 2016 13 July 1, 2020, not 1 Inventories: first first not For certain proteins, antibodies, and chemically based manufactured products, the Company produces larger batches of established products than current sales requirements due to economies of scale through a highly controlled manufacturing process. Accordingly, the manufacturing process for these products has and will continue to produce quantities in excess of forecasted usage. The Company forecasts usage for its products based on several factors including historical demand, current market dynamics, and technological advances. The Company forecasts product usage on an individual product level for a period that is consistent with our ability to reasonably forecast inventory usage for that product. There have been no ASC 330 Property and equipment: Contingent Consideration: may Intangible assets: In conjunction with the Asuragen acquisition that occurred in fiscal year 2021, 2021, 2022 2025, 2026. In fiscal year 2020, 2020 2021. Impairment of long-lived assets and amortizable intangibles: may not not 1 2 3 not The evaluation of asset impairment requires us to make assumptions about future cash flows over the life of the asset being evaluated. These assumptions require significant judgment and actual results may No no 2019, 2020, 2021. Impairment of goodwill: fourth not 1 2 3 4 To analyze goodwill for impairment, we must assign our goodwill to individual reporting units. Identification of reporting units includes an analysis of the components that comprise each of our operating segments, which considers, among other things, the manner in which we operate our business and the availability of discrete financial information. Components of an operating segment are aggregated to form one five 2021, 2020, 2019 April 1 April 1 April 6, 2021. 2021 Goodwill Impairment Analyses In completing our 2021 2017 04, The result of our quantitative assessment indicated that all of the reporting units had a substantial amount of headroom as of April 1, 2021. not June 30, 2021, 2020 Goodwill Impairment Analyses The Company elected to perform a quantitative assessment for all of our reporting units in our 2020 2021 April 1, 2020. not June 30, 2020, 2019 Goodwill Impairment Analyses At the beginning of the quarter ended March 31, 2019, Because our quantitative analysis performed as of January 1, 2019 not The quantitative assessments completed as of January 1, 2019 In conducting our annual goodwill impairment test on April 1, not Based on its annual analysis, the Company determined there was no no June 30, 2019 Other Significant Accounting Policies The following table includes a reference to additional significant accounting policies that are described in other notes to the financial statements, including the note number: Policy Note Fair value measurements 5 Earnings per share 9 Share-based compensation 10 Operating segments 12 Recently Adopted Accounting Pronouncements In February 2016 , 2016 02 , Leases (Topic 842 842 No. 2018 10 2019 01. 2018 11, not 2018 11 842 July 1, 2019 840 842. 842, 842, not 12 7 In June 2016, 2016 13, Financial Instruments - Credit Losses (Topic 326 July 1, 2020 not In August 2018, No. 2018 15, Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract not July 1, 2020. July 1, 2020, In March 2020 , No. 2020 04 , Facilitation of the Effects of Reference Rate Reform on Financial Reporting January 2021 No. 2021 01, Reference Rate Reform (Topic 848 2021 , fourth 2021 not 2021.

Note 2 - Revenue Recognition

Note 2 - Revenue Recognition	12 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	Note 2 . Revenue Recognition: Consumables revenues consist of single-use products and are recognized at a point in time following the transfer of control of such products to the customer, which generally occurs upon shipment. Instruments revenues typically consist of longer-lived assets that, for the substantial majority of sales, are recognized at a point in time in a manner similar to consumables. Service revenues consist of extended warranty contracts, post contract support (“PCS”), and custom development projects that are recognized over time as either the customers receive and consume the benefits of such services simultaneously or the underlying asset being developed has no 2021, not not not not December 1, 2019, July 1, 2020 2021 July 1, 2020 not third The Company elected the exemption to not one one not June 30, 2021 June 30, 2020. Contracts with customers that contain instruments may Payment terms for shipments to end-users are generally net 30 may 30 90 Contract assets include revenues recognized in advance of billings. Contract assets are included within other current assets in the accompanying balance sheet as the amount of time expected to lapse until the company's right to consideration becomes unconditional is less than one June 30, 2021 not Contract liabilities include billings in excess of revenues recognized, such as those resulting from customer advances and deposits and unearned revenue on warranty contracts. Contract liabilities as of June 30, 2021 June 30, 2020 June 30, 2020 June 30, 2021 one Any claims for credit or return of goods must be made within 10 not Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from revenue. Amounts billed to customers for shipping and handling are included in revenue, while the related shipping and handling costs are reflected in cost of products. We have elected the practical expedient that allows us to account for shipping and handling activities that occur after the customer has obtained control of a good as a fulfillment cost, and we accrue costs of shipping and handling when the related revenue is recognized. The following tables present our disaggregated revenue for the periods presented. Revenue by type is as follows: Year ended June 30, 2021 2020 2019 Consumables $ 751,985 $ 602,642 $ 588,979 Instruments 93,782 71,462 67,538 Services 66,416 47,459 38,050 Total product and services revenue, net 912,183 $ 721,563 694,567 Royalty revenues 18,849 17,128 19,439 Total revenues, net $ 931,032 $ 738,691 $ 714,006 Revenue by geography is as follows: Year Ended June 30, 2021 2020 2019 Net sales: United States $ 502,080 $ 404,407 $ 391,191 EMEA, excluding U.K. 204,264 155,289 155,821 U.K. 40,945 30,411 34,975 APAC, excluding Greater China 69,013 60,362 52,913 Greater China 87,556 68,792 57,799 Rest of world 27,174 19,430 21,307 Total external sales $ 931,032 $ 738,691 $ 714,006

Note 3 - Supplemental Balance S

Note 3 - Supplemental Balance Sheet and Cash Flow Information	12 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Supplemental Balance Sheet Disclosures [Text Block]	Note 3. Supplemental Balance Sheet and Cash Flow Information: Available-For-Sale Investments: The fair value of the Company's available-for-sale equity investments as of June 30, 2021 June 30, 2020 June 30, 2021 June 30, 2020. June 30, 2021 2020, June 30, 2021 June 30, 2020 Inventories: Inventories consist of (in thousands): June 30, 2021 2020 Raw materials $ 55,096 $ 51,530 Finished goods (1) 67,108 56,268 Inventories, net $ 122,204 $ 107,798 ( 1 5,456 June 30, 2021 June 30, 2020 12 Property and Equipment: Property and equipment consist of (in thousands): June 30, 2021 2020 Cost: Land $ 8,612 $ 8,516 Buildings and improvements 190,661 184,430 Machinery, equipment and other 198,483 153,704 Property and equipment 397,756 346,650 Accumulated depreciation and amortization (189,849 ) (169,821 ) Property and equipment, net $ 207,907 $ 176,829 Intangibles assets were comprised of the following (in thousands): June 30, Useful Life (years) 2021 2020 Developed technology 9 - 15 $ 552,160 $ 434,653 Trade names 2 - 20 147,640 146,713 Customer relationships 7 - 16 232,493 211,750 Patents 10 2,926 2,475 Other intangibles (1) 5 - 15 6,316 - Definite-lived intangible assets 941,535 795,591 Accumulated amortization (348,267 ) (279,046 ) Definite-lived intangibles assets, net 593,268 516,545 In process research and development 22,700 - Total intangible assets, net $ 615,968 $ 516,545 ( 1 first 2021 third Changes to the carrying amount of net intangible assets consist of (in thousands): June 30, 2021 2020 Beginning balance $ 516,545 $ 579,429 Acquisitions (Note 4) 153,311 - Other additions 5,912 311 Amortization expense (64,940 ) (61,095 ) Currency translation 5,140 (2,100 ) Ending balance $ 615,968 $ 516,545 Amortization expense related to developed technologies included in cost of sales was $36.5 million, $34.5 million, and $33.3 million in fiscal 2021, 2020, 2019, 2021, 2020, 2019 The estimated future amortization expense for intangible assets as of June 30, 2021, excluding any possible future amortization associated with acquired IPR&D which has not 2022 $ 74,482 2023 72,649 2024 69,780 2025 66,523 2026 62,739 Thereafter 247,095 Total $ 593,268 Changes in goodwill by segment and in total consist of (in thousands): Protein Sciences Diagnostics & Genomics Total June 30, 2019 $ 377,407 $ 355,260 $ 732,667 Acquisitions (Note 4) (326 ) - (326 ) Currency Translation (4,000 ) (31 ) (4,031 ) June 30, 2020 $ 373,081 $ 355,229 $ 728,310 Acquisitions (Note 4) 7,848 94,970 102,818 Currency translation 11,788 151 11,939 June 30, 2021 $ 392,717 $ 450,350 $ 843,067 Supplemental Cash Flow Information: Supplemental cash flow information was as follows (in thousands): Year Ended June 30, 2021 2020 2019 Income taxes paid $ 20,952 $ 41,992 $ 36,814 Interest paid 13,576 18,615 21,497 Non-cash activities: Acquisition-related liabilities (1) 23,600 (2,105 ) 12,600 Other intangibles (2) 4,000 - - ( 1 4 5. ( 2 third 2021 not June 30, 2021.

Note 4 - Acquisitions

Note 4 - Acquisitions	12 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Business Combination Disclosure [Text Block]	Note 4 . Acquisitions: We periodically complete business combinations that align with our business strategy. Acquisitions are accounted for using the acquisition method of accounting, which requires, among other things, that assets acquired and liabilities assumed be recognized at fair value as of the acquisition date and that the results of operations of each acquired business be included in our consolidated statements of comprehensive income from their respective dates of acquisitions. Acquisition costs are recorded in selling, general and administrative expenses as incurred. 2021 Eminence Biotechnology On October 20, 2020, April 2, 2021, 57.4%. June 30, 2021, As Eminence met the criteria for consolidation, the transaction was accounted for in accordance with ASC 805, Business Combinations 805 one The goodwill recorded as result of the acquisition represents the strategic benefits of growing the Company’s product portfolio and the expected revenue growth from increased market penetration. The fair value of the noncontrolling interest in Eminence was calculated utilizing cash flow projections discounted to the acquisition date and control premiums calculated using market data. Acquired goodwill is not second 2021. The allocation of purchase consideration related to Eminence was completed in the fourth 2021. June 30, 2021 Preliminary Adjustments to Fair Value Final Allocation at June 30, 2021 Current assets, net of cash $ 3,145 $ - $ 3,145 Equipment and other long-term assets 1,639 - 1,639 Intangible assets: Developed technology 6,778 - 6,778 Customer relationships 2,133 - 2,133 Goodwill 8,811 (963 ) 7,848 Total assets acquired 22,506 (963 ) 21,543 Liabilities 1,436 - 1,436 Deferred income taxes, net 2,320 (963 ) 1,357 Net assets acquired $ 18,750 $ - $ 18,750 Cash paid, net of cash acquired 9,765 - 9,765 Fair value of noncontrolling interest in Eminence 8,985 - 8,985 Net assets acquired $ 18,750 $ - $ 18,750 As summarized in the table, there were adjustments totaling $1.0 million to goodwill during the measurement period. These adjustments relate to refinements within our deferred tax amounts based on factors existing on the acquisition date. not Asuragen, Inc. On April 6, 2021, 805, Business Combinations not fourth 2021. The allocation of purchase consideration related to Asuragen Inc is considered preliminary with provisional amounts primarily rel ated to goodwill and income tax assessment of acquired net operating losses. The Company one 2021 $7.1 3.4 m June 30, 2021 Preliminary allocation at acquisition date and at June 30, 2021 Current assets, net of cash $ 10,422 Equipment and other long-term assets 3,762 Intangible assets: Developed technology 107,000 In-process research and development 22,700 Customer relationships 11,700 Tradenames 2,000 Non-competition agreement 1,000 Goodwill 94,970 Total assets acquired 253,554 Liabilities 4,003 Deferred income taxes, net 15,664 Net assets acquired $ 233,887 Cash paid, net of cash acquired 215,587 Contingent consideration payable 18,300 Net assets acquired $ 233,887 Tangible assets and liabilities acquired were recorded at fair value on the date of close based on management's preliminary assessment. The purchase price allocated to developed technology, in-process research and development, and customer relationships was based on management's preliminary forecasted cash inflows and outflows and using a multiperiod excess earnings method to calculate the fair value of assets purchased. The amount recorded for developed technology is being amortized with the expense reflected in cost of goods sold in the Condensed Consolidated Statement of Earnings and Comprehensive Income. The amortization period for developed technology is estimated to be 14 16 y The net deferred income tax liability represents the net amount of the estimated future impact of adjustments for costs to be recognized as intangible asset amortization, which is not 2019 Quad Technologies On July 2, 2018, not first 2019. 2019. Tangible assets and liabilities acquired were recorded at fair value on the date of close based on management's assessment. The purchase price allocated to developed technology was estimated based on management's forecasted cash inflows and outflows using a multi-period excess earnings method to calculate the fair value of assets purchased. The developed technology asset is being amortized with the expense reflected in cost of goods sold in the Consolidated Statement of Earnings and Comprehensive Income. The amortization period for the developed technology intangible assets acquired in fiscal 2019 not Exosome Diagnostics On August 1, 2018, not first 2019. 2019. Tangible assets and liabilities acquired were recorded at fair value on the date of close based on management's assessment. The purchase price allocated to developed technology, trade names, and customer relationships was based on management's forecasted cash inflows and outflows and using either a relief-from-royalty or a multiperiod excess earnings method to calculate the fair value of assets purchased. The developed technology asset is being amortized with the expense reflected in cost of goods sold in the Condensed Consolidated Statement of Earnings and Comprehensive Income. Amortization expense related to trade names, and customer relationships is reflected in selling, general and administrative expenses in the Consolidated Statement of Earnings and Comprehensive Income. The amortization periods for intangible assets acquired in fiscal 2019 o be recognized as intangible asset amortization, which is not Note: As part of the ExosomeDx acquisition, a certain amount of the cash payment was held in escrow. As part of the finalization of the outstanding amounts held in escrow, the Company recognized a gain of $7.2 million during fiscal year 2020 5. B-MoGen Biotechnologies On June 4, 2019, imately $3.7 million on the transaction within other non-operating income fiscal year 2019 The goodwill recorded as result of the acquisition represents the strategic benefits of growing the Company’s product portfolio and the expected revenue growth from increased market penetration. The goodwill is not fourth 2019. 10 2020 Tangible assets and liabilities acquired were recorded at fair value on the date of close based on management's assessment. The purchase price allocated to developed technology was estimated based on management's forecasted cash inflows and outflows and using a multi-period excess earnings method to calculate the fair value of assets purchased. The developed technology asset is being amortized with the expense reflected in cost of goods sold in the Consolidated Statement of Earnings and Comprehensive Income. The amortization period for the developed technology intangible asset acquired in fiscal 2019 not B-MoGen Biotechnologies Exosome Diagnostics Quad Technologies Current assets, net of cash $ 504 $ 2,611 $ 36 Equipment and other long-term assets 269 2,212 228 Intangible assets: Developed technology 14,000 105,000 12,256 Trade name - 58,000 - Customer relationships 400 2,300 - Goodwill 16,131 105,362 14,481 Total assets acquired 31,304 275,485 27,001 Liabilities 211 3,716 296 Deferred income taxes, net 3,051 16,346 943 Net assets acquired $ 28,042 $ 255,423 $ 25,762 Cash paid, net of cash acquired 17,448 251,623 20,462 Additional consideration (1) 10,594 3,800 5,300 Net assets acquired $ 28,042 $ 255,423 $ 25,762 ( 1 Tangible assets acquired, net of liabilities assumed, were stated at fair value at the date of acquisition based on management's assessment. The purchase price allocated to developed technology, trade names, non-compete agreements and customer relationships was based on management's forecasted cash inflows and outflows and using a relief-from-royalty and multi-period excess earnings method to calculate the fair value of assets purchased. The developed technology is being amortized with the expense reflected in cost of good sold in the Consolidated Statements of Earnings and Comprehensive Income. Amortization expense related to trade names, the non-compete agreement and customer relationships is reflected in selling, general and administrative expenses in the Consolidated Statements of Earnings and Comprehensive Income. The deferred income tax liability represents the estimated future impact of adjustments for the cost to be recognized upon the sale of acquired inventory that was written up to fair value and intangible asset amortization, both of which are not

Note 5 - Fair Value Measurement

Note 5 - Fair Value Measurements	12 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]	Note 5. Fair Value Measurements: The Company’s financial instruments include cash and cash equivalents, available for sale investments, accounts receivable, accounts payable, contingent consideration obligations, derivative instruments, and long-term debt. Fair value is defined as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. This standard also establishes a hierarchy for inputs used in measuring fair value. This standard maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability based on market data obtained from independent sources. Unobservable inputs are inputs that reflect our assumptions about the factors market participants would use in valuing the asset or liability based upon the best information available in the circumstances. The categorization of financial assets and liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is broken down into three 1 2 not 3 one 3 may The following tables provide information by level for financial assets and liabilities that are measured at fair value on a recurring basis (in thousands): Total carrying value as of Fair Value Measurements Using Inputs Considered as June 30, 2021 Level 1 Level 2 Level 3 Assets Equity securities (1) $ 19,963 $ 18,581 $ 1,382 $ - Certificates of deposit (2) 12,500 12,500 - - Derivative instruments - cash flow hedges 275 - 275 - Total Assets $ 32,738 $ 31,081 $ 1,657 $ - Liabilities Contingent consideration $ 29,400 $ - $ - $ 29,400 Derivative instruments - cash flow hedges 8,376 - 8,376 - Total Liabilities $ 37,776 $ - $ 8,376 $ 29,400 Total carrying value as of Fair Value Measurements Using Inputs Considered as June 30, 2020 Level 1 Level 2 Level 3 Assets Equity securities (1) $ 87,842 $ 79,846 $ 7,996 $ - Certificates of deposit (2) 36,426 36,426 - - Total Assets $ 124,268 $ 116,272 $ 7,996 $ - Liabilities Contingent consideration 6,137 $ - - 6,137 Derivative instruments - cash flow hedges 17,331 - 17,331 - Total Liabilities $ 23,468 $ - $ 17,331 $ 6,137 ( 1 June 30, 2021 June 30, 2020 June 30, 2021. June 30, 2020 ( 2 one Fair value measurements of available for sale securities Available for sale securities excluding warrants are measured at fair value using quoted market prices in active markets for identical assets and are therefore classified as Level 1 2 Fair value measurements of derivative instruments In October 2018 , 6 October 2020 October 2021 October 2022. June 2020, October 2020. June 2020 not two December 2020, October 2021. 2021, not June 30, 2021. June 30, 2021, June 30, 2021 In May 2021, November 2022 November 2025. June 30, 2021 Changes in the fair value of the designated hedged instrument are reported as a component of other comprehensive income and reclassified into interest expense over the corresponding term of the cash flow hedge. The Company reclassified $8.6 million to interest expense, $0.5 million to non-operating income for the portion of de-designated variable payments considered probable to not June 30, 2021 October 2018. No May 2021 The Company reclassified $3.5 million, net of taxes, to interest expense during the fiscal year ended June 30, 2020. not June 30, 2020. 2 The Company did not June 30, 2019. Fair value measurements of contingent consideration The Company has $29.4 million, which is the fair value, of contingent consideration related to the Asuragen, Quad, and B-MoGen acquisitions. The Company is required to make contingent consideration payments of up to $105.0 million, $51.0 million, and $38.0 million, respectively, as part of these acquisition agreements. The contingent agreement with Asuragen was based on achieving certain revenue thresholds, the contingent agreement with Quad is based on meeting certain product development milestones and revenue thresholds, and the contingent agreement with B-MoGen is based on meeting certain product development milestones and revenue thresholds. The preliminary fair value of the liabilities for the Asuragen acquisition was $18.3 million as discussed in Note 4. During the fourth 2020, The ultimate settlement of contingent consideration liabilities for the Asuragen, Quad, and B-Mogen acquisitions could deviate from current estimates based on the actual results of the financial measures described above. This liability is considered to be a Level 3 The following table presents a reconciliation of the liability measured at fair value on a recurring basis using significant unobservable inputs (Level 3 June 30, 2021 2020 Fair value at the beginning of period $ 6,137 $ 12,600 Purchase price contingent consideration (Note 4) 18,300 - Payments (337 ) (4,358 ) Gain on escrow settlement - (1,200 ) Change in fair value of contingent consideration 5,300 (905 ) Contingent consideration payable $ 29,400 $ 6,137 Fair value measurements of other financial instruments Cash and cash equivalents, certificates of deposit, accounts receivable, and accounts payable – The carrying amounts reported in the consolidated balance sheets approximate fair value because of the short-term nature of these items. Long-term debt – The carrying amounts reported in the consolidated balance sheets for the amount drawn on our line-of-credit facility and long-term debt approximates fair value because our interest rate is variable and reflects current market rates.

Note 6 - Debt and Other Financi

Note 6 - Debt and Other Financing Arrangements	12 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 6 . Debt and Other Financing Arrangements: On August 1, 2018, may 2022. The Credit Agreement matures on August 1, 2023 August 1, 2018 June 30, 2021 2020,

Note 7 - Leases

Note 7 - Leases	12 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	Note 7. As a lessee, the company leases offices, labs, and manufacturing facilities, as well as vehicles, copiers, and other equipment. The Company adopted ASU No. 2016 02 842, Leases July 1, 2019. The Company recognizes operating lease expense on a straight-line basis over the lease term. Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The discount rate used to calculate present value is the Company’s incremental borrowing rate or, if available, the rate implicit in the lease. The Company determines the incremental borrowing rate for each lease based primarily on its lease term and the economic environment of the applicable country or region. During fiscal year 2021, 2021, The following table summarizes the balance sheet classification of the Company’s operating leases, amounts of right of use assets and lease liabilities, the weighted average remaining lease term, and the weighted average discount rate for the Company’s operating leases (asset and liability amounts are in thousands): Balance Sheet Classification As of: June 30, 2021 Operating leases: Operating lease right of use assets (1) Right of Use Asset $ 73,834 Current operating lease liabilities (1) Operating lease liabilities current $ 11,602 Noncurrent operating lease liabilities (1) Operating lease liabilities 67,625 Total operating lease liabilities $ 79,227 Weighted average remaining lease term (in years): 7.97 Weighted average discount rate: 3.93 % ( 1 June 2021 2022 not June 30, 2021, not The following table summarizes the cash paid for amounts included in the measurement of operating lease liabilities and right of use assets obtained in exchange for new operating lease liabilities for the year ended June 30, 2021 ( For the year ended June 30, 2021 Cash amounts paid on operating lease liabilities(1) $ 13,492 Right of use assets obtained in exchange for lease liabilities 12,144 ( 1 June 30, 2021 The following table summarizes payments by date for the Company’s operating leases, which is then reconciled to our total lease obligation (in thousands): June 30, 2021 Operating Leases 2022 $ 14,349 2023 13,371 2024 11,840 2025 10,780 2026 10,120 Thereafter 32,331 Total $ 92,791 Less: Amounts representing interest 13,564 Total lease obligations 79,227 Certain leases include one five not

Note 8 - Supplemental Equity an

Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss)	12 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Comprehensive Income (Loss) Note [Text Block]	Note 8. Supplemental Equity and Accumulated Other Comprehensive Income (loss): Supplemental Equity The Company has declared cash dividends per share of $ 1.28 June 30, 2021, June 30, 2020, June 30, 2019. June 30, 2021 June 30, 2020, price of $359.81 and 2 79,381 2021, 2020 2019, not Accumulated Other Comprehensive Income (loss) Changes in accumulated other comprehensive income (loss) attributable to Bio-Techne, net of tax, are summarized as follows (in thousands): Unrealized Gains (Losses) on Available- for-Sale Investments Foreign Currency Translation Adjustments Unrealized Gains (Losses) on Derivatives Instruments Total Balance June 30, 2018 $ 24,682 $ (69,496 ) $ - $ (44,814 ) Cumulative effect adjustment for adoption for ASU 2018-02 2,371 - - 2,371 Cumulative effect adjustment for adoption for ASU 2016-01 (27,053 ) - - (27,053 ) Other comprehensive income (loss) before reclassifications - (4,487 ) (9,537 ) (14,024 ) Balance June 30, 2019 $ - $ (73,983 ) $ (9,537 ) $ (83,521 ) Other comprehensive income (loss) before reclassifications - (9,963 ) (7,179 ) (17,142 ) Reclassification from loss on derivatives to interest expense, net of taxes - - 3,464 3,464 Balance June 30, 2020 $ - $ (83,946 ) $ (13,253 ) $ (97,199 ) Other comprehensive income (loss) before reclassifications (2) - 32,848 100 32,948 Reclassification from loss on derivatives to interest expense, net of taxes (1) - - 6,960 6,960 Balance June 30, 2021 $ - $ (51,098 ) $ (6,193 ) $ (57,291 ) ( 1 not 5 June 30, 2021. 2021. 1,908 and June 30, 2021 June 30, 2020 , ( 2

Note 9 - Earnings Per Share

Note 9 - Earnings Per Share	12 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Earnings Per Share [Text Block]	Note 9. Earnings Per Share: The following table reflects the calculation of basic and diluted earnings per share (in thousands, except per share amounts): Year Ended June 30, 2021 2020 2019 Earnings per share – basic: Net earnings, including noncontrolling interest 139,585 229,296 96,072 Less net earnings attributable to noncontrolling interest (825 ) - - Net income $ 140,410 $ 229,296 $ 96,072 Income allocated to participating securities (86 ) (224 ) (105 ) Income available to common shareholders $ 140,324 $ 229,072 $ 95,967 Weighted-average shares outstanding – basic 38,747 38,201 37,781 Earnings per share – basic $ 3.62 $ 6.00 $ 2.54 Earnings per share – diluted: Net income $ 140,410 $ 229,296 $ 96,072 Income allocated to participating securities (86 ) (224 ) (105 ) Income available to common shareholders $ 140,324 $ 229,072 $ 95,967 Weighted-average shares outstanding – basic 38,747 38,201 37,781 Dilutive effect of stock options and restricted stock units 1,736 1,200 1,111 Weighted-average common shares outstanding – diluted 40,483 39,401 38,892 Earnings per share – diluted $ 3.47 $ 5.82 $ 2.47 Basic net income per common share is calculated based on the weighted average number of common shares outstanding during the period. Diluted net income per common share is computed by dividing net income by the weighted average number of common and potentially dilutive common shares outstanding during the period. Potentially dilutive common shares of our stock result from dilutive common stock options and restricted stock units. We use the treasury stock method to calculate the weighted-average shares used in the diluted earnings per share computation. Under the treasury stock method, the proceeds from exercise of an option, the amount of compensation cost, if any, for future service that we have not The dilutive effect of stock options in the above table excludes all options for which the aggregate exercise proceeds exceeded the average market price for the period. The number of potentially dilutive option shares excluded from the calculation was 0 .6 June 30, 2021, 2020 2019,

Note 10 - Share-based Compensat

Note 10 - Share-based Compensation and Other Benefit Plans	12 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	Note 10. Share-based Compensation and Other Benefit Plans: The cost of employee services received in exchange for the award of equity instruments is based on the fair value of the award at the date of grant. Compensation cost is recognized using a straight-line method over the vesting period and is net of estimated forfeitures. Stock option exercises and stock awards are satisfied through the issuance of new shares. Equity incentive plan: 2010 2010 2010 October 2020, 2020 2020 2020 June 30, 2021, 2020 2020 ten 2020 second 2010 2010 2010 2010 1998 1998 2010 1998 June 30, 2021 2020 The fair values of options granted under the Plans were estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions used: Year Ended June 30, 2021 2020 2019 Dividend yield 0.24% 0.67% 0.74% Expected volatility 25% - 30% 22% - 24% 20% - 23% Risk-free interest rates 0.2% - 0.7% 1.3% - 1.9% 2.5% - 3.0% Expected lives (years) 4.4 4.0 4.1 The dividend yield is based on the Company's historical annual cash dividend divided by the market value of the Company's common stock. The expected annualized volatility is based on the Company's historical stock price over a period equivalent to the expected life of the option granted. The risk-free interest rate is based on U.S. Treasury constant maturity interest rates with a term consistent with the expected life of the options granted. Stock option activity under the Plans for the three June 30, 2021, Number of Shares (in thousands) Weighted Average Exercise Price Aggregate Intrinsic Value (millions) Weighted Average Contractual Life (years) Outstanding at June 30, 2018 3,452 $ 105.17 Granted 917 173.89 Forfeited (330 ) 129.93 Exercised (383 ) 95.29 Outstanding at June 30, 2019 3,656 $ 121.16 Granted 752 190.80 Forfeited (56 ) 95.97 Exercised (743 ) 157.45 Outstanding at June 30, 2020 3,609 $ 140.28 Granted 763 277.75 Forfeited (28 ) 214.33 Exercised (627 ) 112.53 Outstanding at June 30, 2021 3,717 $ 172.63 $ 1,031.9 4.1 Exercisable at June 30, 2019: 1,467 98.70 Exercisable at June 30, 2020: 1,564 112.60 Exercisable at June 30, 2021: 1,764 126.44 $ 571.3 3.0 The weighted average fair value of options granted during fiscal 2021, 2020, 2019 2021, 2020, and 2019 2021, 2020, 2019 Restricted common stock activity under the Plans for the three June 30, 2021, Number of Shares (in thousands) Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Term (years) Unvested at June 30, 2018 35 $ 117.39 Granted 15 177.93 Vested (20 ) 116.76 Forfeited - - Unvested at June 30, 2019 30 $ 147.94 Granted 15 193.48 Vested (18 ) 142.12 Forfeited - - Unvested at June 30, 2020 28 $ 177.20 Granted 12 264.73 Vested (17 ) 171.64 Forfeited - - Unvested at June 30, 2021 23 $ 226.07 6.07 The total fair value of restricted shares that vested was $2.8 million for fiscal 2021, 2020, 2019. Restricted stock unit activity under the Plans for the three June 30, 2021, Number of Units (in thousands) Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Term (years) Outstanding at June 30, 2018 148 $ 117.95 Granted 56 170.96 Vested (28 ) 110.86 Forfeited (36 ) 143.72 Outstanding at June 30, 2019 139 $ 134.17 Granted 31 192.08 Vested (51 ) 111.07 Forfeited (3 ) 155.60 Outstanding at June 30, 2020 116 $ 159.25 Granted 31 300.78 Vested (51 ) 130.18 Forfeited - - Outstanding at June 30, 2021 96 $ 220.53 5.36 The total fair value of restricted stock units that vested was $ 6.7 2021, 2020, 2019. three Stock-based compensation cost, inclusive of payroll taxes, of $46.4 million, $32.4 million, and $32.3 million was included in selling, general and administrative expense in fiscal 2021, 2020 2019, 2021. June 30, 2021, 2022 2024 Employee stock purchase plan: 2015, 2014 October 30, 2014, 2021 2020, 2019, Profit sharing and savings plans: 401 June 30, 2021, 2020, 2019, June 30, 2021 d $1.4 million for each of the years ended June 30, 2020 2019. Performance incentive programs: 2021, 21.1 m 2020 2019,

Note 11 - Income Taxes

Note 11 - Income Taxes	12 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Income Tax Disclosure [Text Block]	Note 11. Income Taxes: Income before income taxes was comprised of the following (in thousands): Year Ended June 30, 2021 2020 2019 Domestic $ 95,662 $ 245,365 $ 64,081 Foreign 52,513 31,112 47,934 Income before income taxes $ 148,175 $ 276,477 $ 112,015 The provision for income taxes consisted of the following (in thousands): Year Ended June 30, 2021 2020 2019 Taxes on income consist of: Currently tax provision: Federal $ 15,179 $ 18,976 $ 16,090 State 6,681 6,018 544 Foreign 14,743 8,580 13,329 Total current tax provision 36,603 33,574 29,963 Deferred tax provision: Federal (20,812 ) 14,074 (6,903 ) State (4,962 ) 2,055 (3,977 ) Foreign (2,239 ) (2,522 ) (3,142 ) Total deferred tax provision (28,013 ) 13,607 (14,021 ) Total income tax provision $ 8,590 $ 47,181 $ 15,943 The Company’s effective income tax rate for fiscal 2021 5.8 2021 2020 of $28.1 2021 2020, The Company's effective income tax rate for fiscal 2020 2020 2020 2019 The Company's discrete tax benefits in fiscal 2021 $28.1 The Company's discrete tax benefits in fiscal 2020 The Company's discrete tax benefits in fiscal 2019 2019 The Company continues to monitor newly enacted regulations, clarifications, and changes in guidance the Tax Cuts and Jobs Act “Tax Act”, which was enacted on December 22, 2017. may The following is a reconciliation of the federal tax calculated at the statutory rate of to the actual income taxes provided: Year Ended June 30, 2021 2020 2019 Income tax expense at federal statutory rate 21.0 % 21.0 % 21.0 % State income taxes, net of federal benefit 0.6 2.3 (1.5 ) Research and development tax credit (1.8 ) (0.7 ) (1.6 ) Contingent consideration adjustment 0.8 (0.2 ) (0.4 ) Foreign tax rate differences 0.8 (0.2 ) 0.2 Option exercises (16.9 ) (5.7 ) (5.8 ) U.S. taxation of foreign earnings (0.1 ) 0.9 3.7 Foreign derived intangible income (5.1 ) (0.9 ) (2.0 ) Executive compensation limitations 6.5 1.6 0.4 Other, net 0.0 (1.0 ) 0.2 Effective tax rate 5.8 % 17.1 % 14.2 % Deferred taxes on the Consolidated Balance Sheets consisted of the following temporary differences (in thousands): June 30 2021 2020 Inventory $ 6,730 $ 7,769 Net operating loss carryovers 31,345 25,707 Tax credit carryovers 14,486 9,568 Excess tax basis in equity investments 2,429 2,423 Deferred compensation 11,108 10,755 Derivative - cash flow hedge 1,908 4,058 Lease liability 17,016 16,256 Other 8,526 4,340 Valuation allowance (6,665 ) (7,523 ) Deferred tax assets 86,883 73,353 Net unrealized gain on available-for-sale investments (3,159 ) (19,102 ) Intangible asset amortization (150,765 ) (128,279 ) Depreciation (9,099 ) (10,764 ) Right of use asset (15,868 ) (15,118 ) Other (1,117 ) (1,180 ) Deferred tax liabilities (180,008 ) (174,443 ) Net deferred tax liabilities $ (93,125 ) $ (101,090 ) A deferred tax valuation allowance is required when it is more likely than not not June 30, 20 21 As of June 30, 2021, $6.7 not not As of June 30, 2021, $92.1 m $129.6 m 4 not 382. June 30, 2021, $13.9 The net operating loss carryforwards expire between fiscal 2022 2036. June 30, 2021, million and $4.4 m 2028 2038. no The Company has not mately $223 mill y. The transition tax included as part of the Tax Act resulted in the previously untaxed foreign earnings being included in the federal and state fiscal 2018 one No We continue to analyze our global working capital requirements and the potential tax liabilities that would be incurred if the non-U.S. subsidiaries distribute cash to the U.S. parent, which include local country withholding tax and potential U.S. state taxation. In addition, we anticipate that further guidance from the IRS and US Treasury related to the Tax Act could impact the amount of any related taxes. Therefore, it is not The following is a reconciliation of the beginning and ending balance of unrecognized tax benefits (in thousands): Year Ended June 30, 2021 2020 2019 Beginning balance $ 4,297 $ 5,032 $ 1,947 Additions due to acquisitions - - 900 Additions for tax positions of prior year 4,038 306 2,185 Decrease in unrecognized tax benefits for prior year positions (778 ) (1,041 ) - Settlements (286 ) - - Ending balances $ 7,271 $ 4,297 $ 5,032 Included in the balance of unrecognized tax benefits at June 30, 2021 June 30, 2021 not not twelve may 2017 three five one

Note 12 - Segment Information

Note 12 - Segment Information	12 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	Note 12. Segment Information: The Company operates under two operating segments, Protein Sciences and Diagnostics and Genomics. The Company's Protein Sciences segment is comprised of the reagent solutions and analytical solutions. These businesses manufacture consumables used for conducting laboratory experiments by both industry and academic scientists within the biotechnology and biomedical life science fields. No customer in the Protein Sciences segment accounted for more than 10% June 30, 2021, 2020, 2019. The Company's Diagnostics and Genomics segment is comprised of diagnostics reagents, genomics, and our Exosome and Asuragen acquisitions. Diagnostics reagents develops and manufactures a range of controls and calibrators used with diagnostic equipment and as proficiency testing tools, as well as other reagents incorporated into diagnostic kits. Genomics, Exosome, and Asuragen consists of Genomics and Exosome products and sells a portfolio of clinical molecular diagnostic oncology assays, as well as tissue-based in-situ hybridization assays for research in clinical use. No customer in the Diagnostics and Genomics segment accounted for more than 10% June 30, 2021, 2020, 2019. There are no Following is financial information relating to the operating segments (in thousands): Year Ended June 30, 2021 2020 2019 Net sales: Protein Sciences $ 704,564 $ 555,352 $ 543,159 Diagnostics and Genomics 227,744 184,549 171,674 Intersegment (1,276 ) (1,210 ) (827 ) Consolidated net sales $ 931,032 $ 738,691 $ 714,006 Operating Income: Protein Sciences $ 328,837 $ 234,929 $ 240,919 Diagnostics and Genomics 38,425 14,965 10,079 Segment operating income 367,262 249,894 250,998 Costs recognized upon sale of acquired inventory (1,565 ) - (3,739 ) Amortization of acquired intangible assets (64,239 ) (60,865 ) (58,550 ) Gain on escrow settlement - 7,169 - Acquisition related expenses (7,114 ) (416 ) (2,282 ) Restructuring costs (142 ) (87 ) - Stock-based compensation, inclusive of employer taxes (51,846 ) (34,262 ) (33,057 ) Corporate general, selling and administrative expenses (5,060 ) (4,015 ) (6,651 ) Consolidated operating income $ 237,296 $ 157,419 $ 146,719 The Company has some integrated facilities that serve multiple segments. As such, asset and capital expenditure information by operating segment has not not not not The Company has disclosed sales by geographic area based on the location of the customer or distributor in Note 2. 2. Year Ended June 30, 2021 2020 2019 Consumables revenue - Protein Sciences $ 557,037 $ 431,052 $ 430,655 Consumables revenue - Diagnostics and Genomics 194,948 171,590 158,324 Total consumable revenue $ 751,985 $ 602,642 $ 588,979 The following is financial information relating to geographic areas (in thousands): Year ended June 30, Long-lived assets: 2021 2020 United States and Canada $ 190,501 $ 162,039 Europe 13,949 13,120 Asia 3,457 1,670 Total long-lived assets $ 207,907 $ 176,829 Intangible assets: United States and Canada $ 594,512 $ 499,875 Europe 9,369 12,349 Asia 12,087 4,321 Total intangible assets $ 615,968 $ 516,545 Long-lived assets are comprised of land, buildings and improvements and equipment, net of accumulated depreciation and other assets.

Note 13 - Subsequent Events

Note 13 - Subsequent Events	12 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Subsequent Events [Text Block]	Note 13. Subsequent Events: None

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of estimates:
Consolidation, Policy [Policy Text Block]	Principles of consolidation: one 4
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Translation of foreign financial statements:
Revenue [Policy Text Block]	Revenue recognition: ASC 606 Revenue from Contracts with Customers July 1, 2018 606 606 2 ASC 606
Research and Development Expense, Policy [Policy Text Block]	Research and development:
Advertising Cost [Policy Text Block]	Advertising costs: 2021, 2020, 2019
Income Tax, Policy [Policy Text Block]	Income taxes: not fifty 11
Comprehensive Income, Policy [Policy Text Block]	Comprehensive income: not
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and cash equivalents: three
Marketable Securities, Policy [Policy Text Block]	Available-for-sale investments: three six 2018 02, July 1, 2018.
Accounts Receivable [Policy Text Block]	Trade accounts receivable and allowances: not 2016 13 July 1, 2020, not 1
Inventory, Policy [Policy Text Block]	Inventories: first first not For certain proteins, antibodies, and chemically based manufactured products, the Company produces larger batches of established products than current sales requirements due to economies of scale through a highly controlled manufacturing process. Accordingly, the manufacturing process for these products has and will continue to produce quantities in excess of forecasted usage. The Company forecasts usage for its products based on several factors including historical demand, current market dynamics, and technological advances. The Company forecasts product usage on an individual product level for a period that is consistent with our ability to reasonably forecast inventory usage for that product. There have been no ASC 330
Property, Plant and Equipment, Policy [Policy Text Block]	Property and equipment:
Contingent Consideration, Policy [Policy Text Block]	Contingent Consideration: may
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Intangible assets: In conjunction with the Asuragen acquisition that occurred in fiscal year 2021, 2021, 2022 2025, 2026. In fiscal year 2020, 2020 2021.
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]	Impairment of long-lived assets and amortizable intangibles: may not not 1 2 3 not The evaluation of asset impairment requires us to make assumptions about future cash flows over the life of the asset being evaluated. These assumptions require significant judgment and actual results may No no 2019, 2020, 2021. Impairment of goodwill: fourth not 1 2 3 4 To analyze goodwill for impairment, we must assign our goodwill to individual reporting units. Identification of reporting units includes an analysis of the components that comprise each of our operating segments, which considers, among other things, the manner in which we operate our business and the availability of discrete financial information. Components of an operating segment are aggregated to form one five 2021, 2020, 2019 April 1 April 1 April 6, 2021. 2021 Goodwill Impairment Analyses In completing our 2021 2017 04, The result of our quantitative assessment indicated that all of the reporting units had a substantial amount of headroom as of April 1, 2021. not June 30, 2021, 2020 Goodwill Impairment Analyses The Company elected to perform a quantitative assessment for all of our reporting units in our 2020 2021 April 1, 2020. not June 30, 2020, 2019 Goodwill Impairment Analyses At the beginning of the quarter ended March 31, 2019, Because our quantitative analysis performed as of January 1, 2019 not The quantitative assessments completed as of January 1, 2019 In conducting our annual goodwill impairment test on April 1, not Based on its annual analysis, the Company determined there was no no June 30, 2019
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Pronouncements In February 2016 , 2016 02 , Leases (Topic 842 842 No. 2018 10 2019 01. 2018 11, not 2018 11 842 July 1, 2019 840 842. 842, 842, not 12 7 In June 2016, 2016 13, Financial Instruments - Credit Losses (Topic 326 July 1, 2020 not In August 2018, No. 2018 15, Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract not July 1, 2020. July 1, 2020, In March 2020 , No. 2020 04 , Facilitation of the Effects of Reference Rate Reform on Financial Reporting January 2021 No. 2021 01, Reference Rate Reform (Topic 848 2021 , fourth 2021 not 2021.

Note 2 - Revenue Recognition (T

Note 2 - Revenue Recognition (Tables)	12 Months Ended
	Jun. 30, 2021
Notes Tables
Disaggregation of Revenue [Table Text Block]	Year ended June 30, 2021 2020 2019 Consumables $ 751,985 $ 602,642 $ 588,979 Instruments 93,782 71,462 67,538 Services 66,416 47,459 38,050 Total product and services revenue, net 912,183 $ 721,563 694,567 Royalty revenues 18,849 17,128 19,439 Total revenues, net $ 931,032 $ 738,691 $ 714,006 Year Ended June 30, 2021 2020 2019 Net sales: United States $ 502,080 $ 404,407 $ 391,191 EMEA, excluding U.K. 204,264 155,289 155,821 U.K. 40,945 30,411 34,975 APAC, excluding Greater China 69,013 60,362 52,913 Greater China 87,556 68,792 57,799 Rest of world 27,174 19,430 21,307 Total external sales $ 931,032 $ 738,691 $ 714,006

Note 3 - Supplemental Balance_2

Note 3 - Supplemental Balance Sheet and Cash Flow Information (Tables)	12 Months Ended
	Jun. 30, 2021
Notes Tables
Schedule of Inventory, Current [Table Text Block]	June 30, 2021 2020 Raw materials $ 55,096 $ 51,530 Finished goods (1) 67,108 56,268 Inventories, net $ 122,204 $ 107,798
Property, Plant and Equipment [Table Text Block]	June 30, 2021 2020 Cost: Land $ 8,612 $ 8,516 Buildings and improvements 190,661 184,430 Machinery, equipment and other 198,483 153,704 Property and equipment 397,756 346,650 Accumulated depreciation and amortization (189,849 ) (169,821 ) Property and equipment, net $ 207,907 $ 176,829
Schedule of Intangible Assets and Goodwill [Table Text Block]	June 30, Useful Life (years) 2021 2020 Developed technology 9 - 15 $ 552,160 $ 434,653 Trade names 2 - 20 147,640 146,713 Customer relationships 7 - 16 232,493 211,750 Patents 10 2,926 2,475 Other intangibles (1) 5 - 15 6,316 - Definite-lived intangible assets 941,535 795,591 Accumulated amortization (348,267 ) (279,046 ) Definite-lived intangibles assets, net 593,268 516,545 In process research and development 22,700 - Total intangible assets, net $ 615,968 $ 516,545
Schedule of Finite-Lived Intangible Assets [Table Text Block]	June 30, 2021 2020 Beginning balance $ 516,545 $ 579,429 Acquisitions (Note 4) 153,311 - Other additions 5,912 311 Amortization expense (64,940 ) (61,095 ) Currency translation 5,140 (2,100 ) Ending balance $ 615,968 $ 516,545
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	2022 $ 74,482 2023 72,649 2024 69,780 2025 66,523 2026 62,739 Thereafter 247,095 Total $ 593,268
Schedule of Goodwill [Table Text Block]	Protein Sciences Diagnostics & Genomics Total June 30, 2019 $ 377,407 $ 355,260 $ 732,667 Acquisitions (Note 4) (326 ) - (326 ) Currency Translation (4,000 ) (31 ) (4,031 ) June 30, 2020 $ 373,081 $ 355,229 $ 728,310 Acquisitions (Note 4) 7,848 94,970 102,818 Currency translation 11,788 151 11,939 June 30, 2021 $ 392,717 $ 450,350 $ 843,067
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]	Year Ended June 30, 2021 2020 2019 Income taxes paid $ 20,952 $ 41,992 $ 36,814 Interest paid 13,576 18,615 21,497 Non-cash activities: Acquisition-related liabilities (1) 23,600 (2,105 ) 12,600 Other intangibles (2) 4,000 - -

Note 4 - Acquisitions (Tables)

Note 4 - Acquisitions (Tables)	12 Months Ended
	Jun. 30, 2021
Notes Tables
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	Preliminary Adjustments to Fair Value Final Allocation at June 30, 2021 Current assets, net of cash $ 3,145 $ - $ 3,145 Equipment and other long-term assets 1,639 - 1,639 Intangible assets: Developed technology 6,778 - 6,778 Customer relationships 2,133 - 2,133 Goodwill 8,811 (963 ) 7,848 Total assets acquired 22,506 (963 ) 21,543 Liabilities 1,436 - 1,436 Deferred income taxes, net 2,320 (963 ) 1,357 Net assets acquired $ 18,750 $ - $ 18,750 Cash paid, net of cash acquired 9,765 - 9,765 Fair value of noncontrolling interest in Eminence 8,985 - 8,985 Net assets acquired $ 18,750 $ - $ 18,750 Preliminary allocation at acquisition date and at June 30, 2021 Current assets, net of cash $ 10,422 Equipment and other long-term assets 3,762 Intangible assets: Developed technology 107,000 In-process research and development 22,700 Customer relationships 11,700 Tradenames 2,000 Non-competition agreement 1,000 Goodwill 94,970 Total assets acquired 253,554 Liabilities 4,003 Deferred income taxes, net 15,664 Net assets acquired $ 233,887 Cash paid, net of cash acquired 215,587 Contingent consideration payable 18,300 Net assets acquired $ 233,887 B-MoGen Biotechnologies Exosome Diagnostics Quad Technologies Current assets, net of cash $ 504 $ 2,611 $ 36 Equipment and other long-term assets 269 2,212 228 Intangible assets: Developed technology 14,000 105,000 12,256 Trade name - 58,000 - Customer relationships 400 2,300 - Goodwill 16,131 105,362 14,481 Total assets acquired 31,304 275,485 27,001 Liabilities 211 3,716 296 Deferred income taxes, net 3,051 16,346 943 Net assets acquired $ 28,042 $ 255,423 $ 25,762 Cash paid, net of cash acquired 17,448 251,623 20,462 Additional consideration (1) 10,594 3,800 5,300 Net assets acquired $ 28,042 $ 255,423 $ 25,762

Note 5 - Fair Value Measureme_2

Note 5 - Fair Value Measurements (Tables)	12 Months Ended
	Jun. 30, 2021
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Total carrying value as of Fair Value Measurements Using Inputs Considered as June 30, 2021 Level 1 Level 2 Level 3 Assets Equity securities (1) $ 19,963 $ 18,581 $ 1,382 $ - Certificates of deposit (2) 12,500 12,500 - - Derivative instruments - cash flow hedges 275 - 275 - Total Assets $ 32,738 $ 31,081 $ 1,657 $ - Liabilities Contingent consideration $ 29,400 $ - $ - $ 29,400 Derivative instruments - cash flow hedges 8,376 - 8,376 - Total Liabilities $ 37,776 $ - $ 8,376 $ 29,400 Total carrying value as of Fair Value Measurements Using Inputs Considered as June 30, 2020 Level 1 Level 2 Level 3 Assets Equity securities (1) $ 87,842 $ 79,846 $ 7,996 $ - Certificates of deposit (2) 36,426 36,426 - - Total Assets $ 124,268 $ 116,272 $ 7,996 $ - Liabilities Contingent consideration 6,137 $ - - 6,137 Derivative instruments - cash flow hedges 17,331 - 17,331 - Total Liabilities $ 23,468 $ - $ 17,331 $ 6,137
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	June 30, 2021 2020 Fair value at the beginning of period $ 6,137 $ 12,600 Purchase price contingent consideration (Note 4) 18,300 - Payments (337 ) (4,358 ) Gain on escrow settlement - (1,200 ) Change in fair value of contingent consideration 5,300 (905 ) Contingent consideration payable $ 29,400 $ 6,137

Note 7 - Leases (Tables)

Note 7 - Leases (Tables)	12 Months Ended
	Jun. 30, 2021
Notes Tables
Lessee, Operating Lease, Asset and Liabilities [Table Text Block]	Balance Sheet Classification As of: June 30, 2021 Operating leases: Operating lease right of use assets (1) Right of Use Asset $ 73,834 Current operating lease liabilities (1) Operating lease liabilities current $ 11,602 Noncurrent operating lease liabilities (1) Operating lease liabilities 67,625 Total operating lease liabilities $ 79,227 Weighted average remaining lease term (in years): 7.97 Weighted average discount rate: 3.93 %
Lessee, Operating Lease, Cash Flow Information [Table Text Block]	For the year ended June 30, 2021 Cash amounts paid on operating lease liabilities(1) $ 13,492 Right of use assets obtained in exchange for lease liabilities 12,144
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	June 30, 2021 Operating Leases 2022 $ 14,349 2023 13,371 2024 11,840 2025 10,780 2026 10,120 Thereafter 32,331 Total $ 92,791 Less: Amounts representing interest 13,564 Total lease obligations 79,227

Note 8 - Supplemental Equity _2

Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Tables)	12 Months Ended
	Jun. 30, 2021
Notes Tables
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Unrealized Gains (Losses) on Available- for-Sale Investments Foreign Currency Translation Adjustments Unrealized Gains (Losses) on Derivatives Instruments Total Balance June 30, 2018 $ 24,682 $ (69,496 ) $ - $ (44,814 ) Cumulative effect adjustment for adoption for ASU 2018-02 2,371 - - 2,371 Cumulative effect adjustment for adoption for ASU 2016-01 (27,053 ) - - (27,053 ) Other comprehensive income (loss) before reclassifications - (4,487 ) (9,537 ) (14,024 ) Balance June 30, 2019 $ - $ (73,983 ) $ (9,537 ) $ (83,521 ) Other comprehensive income (loss) before reclassifications - (9,963 ) (7,179 ) (17,142 ) Reclassification from loss on derivatives to interest expense, net of taxes - - 3,464 3,464 Balance June 30, 2020 $ - $ (83,946 ) $ (13,253 ) $ (97,199 ) Other comprehensive income (loss) before reclassifications (2) - 32,848 100 32,948 Reclassification from loss on derivatives to interest expense, net of taxes (1) - - 6,960 6,960 Balance June 30, 2021 $ - $ (51,098 ) $ (6,193 ) $ (57,291 )

Note 9 - Earnings Per Share (Ta

Note 9 - Earnings Per Share (Tables)	12 Months Ended
	Jun. 30, 2021
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Year Ended June 30, 2021 2020 2019 Earnings per share – basic: Net earnings, including noncontrolling interest 139,585 229,296 96,072 Less net earnings attributable to noncontrolling interest (825 ) - - Net income $ 140,410 $ 229,296 $ 96,072 Income allocated to participating securities (86 ) (224 ) (105 ) Income available to common shareholders $ 140,324 $ 229,072 $ 95,967 Weighted-average shares outstanding – basic 38,747 38,201 37,781 Earnings per share – basic $ 3.62 $ 6.00 $ 2.54 Earnings per share – diluted: Net income $ 140,410 $ 229,296 $ 96,072 Income allocated to participating securities (86 ) (224 ) (105 ) Income available to common shareholders $ 140,324 $ 229,072 $ 95,967 Weighted-average shares outstanding – basic 38,747 38,201 37,781 Dilutive effect of stock options and restricted stock units 1,736 1,200 1,111 Weighted-average common shares outstanding – diluted 40,483 39,401 38,892 Earnings per share – diluted $ 3.47 $ 5.82 $ 2.47

Note 10 - Share-based Compens_2

Note 10 - Share-based Compensation and Other Benefit Plans (Tables)	12 Months Ended
	Jun. 30, 2021
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Year Ended June 30, 2021 2020 2019 Dividend yield 0.24% 0.67% 0.74% Expected volatility 25% - 30% 22% - 24% 20% - 23% Risk-free interest rates 0.2% - 0.7% 1.3% - 1.9% 2.5% - 3.0% Expected lives (years) 4.4 4.0 4.1
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Number of Shares (in thousands) Weighted Average Exercise Price Aggregate Intrinsic Value (millions) Weighted Average Contractual Life (years) Outstanding at June 30, 2018 3,452 $ 105.17 Granted 917 173.89 Forfeited (330 ) 129.93 Exercised (383 ) 95.29 Outstanding at June 30, 2019 3,656 $ 121.16 Granted 752 190.80 Forfeited (56 ) 95.97 Exercised (743 ) 157.45 Outstanding at June 30, 2020 3,609 $ 140.28 Granted 763 277.75 Forfeited (28 ) 214.33 Exercised (627 ) 112.53 Outstanding at June 30, 2021 3,717 $ 172.63 $ 1,031.9 4.1 Exercisable at June 30, 2019: 1,467 98.70 Exercisable at June 30, 2020: 1,564 112.60 Exercisable at June 30, 2021: 1,764 126.44 $ 571.3 3.0
Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]	Number of Shares (in thousands) Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Term (years) Unvested at June 30, 2018 35 $ 117.39 Granted 15 177.93 Vested (20 ) 116.76 Forfeited - - Unvested at June 30, 2019 30 $ 147.94 Granted 15 193.48 Vested (18 ) 142.12 Forfeited - - Unvested at June 30, 2020 28 $ 177.20 Granted 12 264.73 Vested (17 ) 171.64 Forfeited - - Unvested at June 30, 2021 23 $ 226.07 6.07 Number of Units (in thousands) Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Term (years) Outstanding at June 30, 2018 148 $ 117.95 Granted 56 170.96 Vested (28 ) 110.86 Forfeited (36 ) 143.72 Outstanding at June 30, 2019 139 $ 134.17 Granted 31 192.08 Vested (51 ) 111.07 Forfeited (3 ) 155.60 Outstanding at June 30, 2020 116 $ 159.25 Granted 31 300.78 Vested (51 ) 130.18 Forfeited - - Outstanding at June 30, 2021 96 $ 220.53 5.36

Note 11 - Income Taxes (Tables)

Note 11 - Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2021
Notes Tables
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Year Ended June 30, 2021 2020 2019 Domestic $ 95,662 $ 245,365 $ 64,081 Foreign 52,513 31,112 47,934 Income before income taxes $ 148,175 $ 276,477 $ 112,015 Year Ended June 30, 2021 2020 2019 Taxes on income consist of: Currently tax provision: Federal $ 15,179 $ 18,976 $ 16,090 State 6,681 6,018 544 Foreign 14,743 8,580 13,329 Total current tax provision 36,603 33,574 29,963 Deferred tax provision: Federal (20,812 ) 14,074 (6,903 ) State (4,962 ) 2,055 (3,977 ) Foreign (2,239 ) (2,522 ) (3,142 ) Total deferred tax provision (28,013 ) 13,607 (14,021 ) Total income tax provision $ 8,590 $ 47,181 $ 15,943
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Year Ended June 30, 2021 2020 2019 Income tax expense at federal statutory rate 21.0 % 21.0 % 21.0 % State income taxes, net of federal benefit 0.6 2.3 (1.5 ) Research and development tax credit (1.8 ) (0.7 ) (1.6 ) Contingent consideration adjustment 0.8 (0.2 ) (0.4 ) Foreign tax rate differences 0.8 (0.2 ) 0.2 Option exercises (16.9 ) (5.7 ) (5.8 ) U.S. taxation of foreign earnings (0.1 ) 0.9 3.7 Foreign derived intangible income (5.1 ) (0.9 ) (2.0 ) Executive compensation limitations 6.5 1.6 0.4 Other, net 0.0 (1.0 ) 0.2 Effective tax rate 5.8 % 17.1 % 14.2 %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	June 30 2021 2020 Inventory $ 6,730 $ 7,769 Net operating loss carryovers 31,345 25,707 Tax credit carryovers 14,486 9,568 Excess tax basis in equity investments 2,429 2,423 Deferred compensation 11,108 10,755 Derivative - cash flow hedge 1,908 4,058 Lease liability 17,016 16,256 Other 8,526 4,340 Valuation allowance (6,665 ) (7,523 ) Deferred tax assets 86,883 73,353 Net unrealized gain on available-for-sale investments (3,159 ) (19,102 ) Intangible asset amortization (150,765 ) (128,279 ) Depreciation (9,099 ) (10,764 ) Right of use asset (15,868 ) (15,118 ) Other (1,117 ) (1,180 ) Deferred tax liabilities (180,008 ) (174,443 ) Net deferred tax liabilities $ (93,125 ) $ (101,090 )
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]	Year Ended June 30, 2021 2020 2019 Beginning balance $ 4,297 $ 5,032 $ 1,947 Additions due to acquisitions - - 900 Additions for tax positions of prior year 4,038 306 2,185 Decrease in unrecognized tax benefits for prior year positions (778 ) (1,041 ) - Settlements (286 ) - - Ending balances $ 7,271 $ 4,297 $ 5,032

Note 12 - Segment Information (

Note 12 - Segment Information (Tables)	12 Months Ended
	Jun. 30, 2021
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Year Ended June 30, 2021 2020 2019 Net sales: Protein Sciences $ 704,564 $ 555,352 $ 543,159 Diagnostics and Genomics 227,744 184,549 171,674 Intersegment (1,276 ) (1,210 ) (827 ) Consolidated net sales $ 931,032 $ 738,691 $ 714,006 Operating Income: Protein Sciences $ 328,837 $ 234,929 $ 240,919 Diagnostics and Genomics 38,425 14,965 10,079 Segment operating income 367,262 249,894 250,998 Costs recognized upon sale of acquired inventory (1,565 ) - (3,739 ) Amortization of acquired intangible assets (64,239 ) (60,865 ) (58,550 ) Gain on escrow settlement - 7,169 - Acquisition related expenses (7,114 ) (416 ) (2,282 ) Restructuring costs (142 ) (87 ) - Stock-based compensation, inclusive of employer taxes (51,846 ) (34,262 ) (33,057 ) Corporate general, selling and administrative expenses (5,060 ) (4,015 ) (6,651 ) Consolidated operating income $ 237,296 $ 157,419 $ 146,719 Year Ended June 30, 2021 2020 2019 Consumables revenue - Protein Sciences $ 557,037 $ 431,052 $ 430,655 Consumables revenue - Diagnostics and Genomics 194,948 171,590 158,324 Total consumable revenue $ 751,985 $ 602,642 $ 588,979 Year ended June 30, Long-lived assets: 2021 2020 United States and Canada $ 190,501 $ 162,039 Europe 13,949 13,120 Asia 3,457 1,670 Total long-lived assets $ 207,907 $ 176,829 Intangible assets: United States and Canada $ 594,512 $ 499,875 Europe 9,369 12,349 Asia 12,087 4,321 Total intangible assets $ 615,968 $ 516,545

Note 1 - Description of Busin_2

Note 1 - Description of Business and Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2021		Jun. 30, 2020	Jun. 30, 2019	Jul. 01, 2020	Jul. 01, 2019
Advertising Expense	$ 4,700		$ 4,200	$ 4,100
Amortization of Intangible Assets, Total	64,940		61,095
Operating Lease, Liability, Total	79,227
Operating Lease, Right-of-Use Asset	73,834	[1]	71,465
Retained Earnings (Accumulated Deficit), Ending Balance	1,085,461		1,057,470
Deferred Income Tax Liabilities, Net, Total	93,125		101,090
Accounting Standards Update 2016-02 [Member]
Operating Lease, Liability, Total						$ 80,600
Operating Lease, Right-of-Use Asset						79,500
Retained Earnings (Accumulated Deficit), Ending Balance						800
Deferred Income Tax Liabilities, Net, Total						(300)
Deferred Rent Credit						$ 4,000
Accounting Standards Update 2016-13 [Member]
Retained Earnings (Accumulated Deficit), Ending Balance					$ (300)
Trade Names [Member]
Amortization of Intangible Assets, Total	1,400		1,300
Finite-Lived Intangible Asset, Expected Amortization, Year One	5,700		$ 600
Finite-Lived Intangible Asset, Expected Amortization, Year Five	$ 4,300
Minimum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	1 year
Minimum [Member] | Trade Names [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	2 years
Maximum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	20 years
Maximum [Member] | Trade Names [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	20 years
Equipment [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)	3 years
Equipment [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)	5 years
Building, Building Improvements and Leasehold Improvements [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)	5 years
Building, Building Improvements and Leasehold Improvements [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)	40 years
[1]	The right of use asset, current operating lease liabilities, and noncurrent lease liabilities on the Consolidated Balance Sheet exclude a definitive agreement entered into by the Company in June 2021 for a 25,000 square foot facility in Dublin, Ireland for the next 25 years with annual rental impact of $0.3 million. The lease will commence during fiscal 2022 after construction is completed by the landlord. As the lease has not commenced as of June 30, 2021, the related asset and liability were not recorded.

Note 2 - Revenue Recognition (D

Note 2 - Revenue Recognition (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Proceeds from Laboratory Services Reimbursed by Medicare	$ 0.5
Contract with Customer, Liability, Total	20	$ 14.2
Contract with Customer, Liability, Revenue Recognized	$ 10.6

Note 2 - Revenue Recognition -

Note 2 - Revenue Recognition - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Revenues, net	$ 931,032	$ 738,691	$ 714,006
UNITED STATES
Revenues, net	502,080	404,407	391,191
EMEA, excluding U.K. [Member]
Revenues, net	204,264	155,289	155,821
UNITED KINGDOM
Revenues, net	40,945	30,411	34,975
APAC, excluding Greater China [Member]
Revenues, net	69,013	60,362	52,913
CHINA
Revenues, net	87,556	68,792	57,799
Rest of World [Member]
Revenues, net	27,174	19,430	21,307
Consumables [Member]
Revenues, net	751,985	602,642	588,979
Instruments [Member]
Revenues, net	93,782	71,462	67,538
Service [Member]
Revenues, net	66,416	47,459	38,050
Product and Services [Member]
Revenues, net	912,183	721,563	694,567
Royalty [Member]
Revenues, net	$ 18,849	$ 17,128	$ 19,439

Note 3 - Supplemental Balance_3

Note 3 - Supplemental Balance Sheet and Cash Flow Information (Details Textual) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended	12 Months Ended
		Sep. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Available-for-sale Securities, Total			$ 20,000	$ 87,800
Debt Securities, Available-for-sale, Total			12,500	36,400
Finite-lived Intangible Assets Acquired			153,311	0
Amortization of Intangible Assets, Total			64,940	61,095
Noncash or Part Noncash Acquisition, Intangible Assets Acquired	[1]		4,000	0	$ 0
Patented Technology [Member]
Finite-lived Intangible Assets Acquired		$ 5,000
Noncash or Part Noncash Acquisition, Intangible Assets Acquired			4,000
Developed Technology Rights [Member] | Cost of Sales [Member]
Amortization of Intangible Assets, Total			36,500	34,500	33,300
Trade Names, Customer Relationships, Non-Compete Agreements, and Patents [Member] | Selling, General and Administrative Expenses [Member]
Amortization of Intangible Assets, Total			28,400	26,600	$ 25,400
Other Noncurrent Assets [Member]
Inventory, Finished Goods, Net of Reserves, Non-current			5,456	4,646
ChemoCentryx, Inc (CCXI) [Member]
Available-for-sale Equity Securities, Amortized Cost Basis, Total			$ 6,600	$ 6,600
ChemoCentryx, Inc (CCXI) [Member]
Share Price (in dollars per share)			$ 13.39	$ 57.54
[1]	$4.0 million of the third party patented technology acquired in fiscal 2021 was a non-cash activity within the consolidated statement of cash flows as a cash payment was not made within the fiscal year ended June 30, 2021.

Note 3 - Supplemental Balance_4

Note 3 - Supplemental Balance Sheet and Cash Flow Information - Inventories (Details) - USD ($) $ in Thousands		Jun. 30, 2021	Jun. 30, 2020
Raw materials		$ 55,096	$ 51,530
Finished goods	[1]	67,108	56,268
Inventories, net		$ 122,204	$ 107,798
[1]	Finished goods inventory of $5,456 and $4,646 is included within other long-term assets in the June 30, 2021 and June 30, 2020 Balance Sheets, respectively, as it forecasted to be sold after the 12 months subsequent to the consolidated balance sheet date.

Note 3 - Supplemental Balance_5

Note 3 - Supplemental Balance Sheet and Cash Flow Information - Property and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Jun. 30, 2020
Property and equipment, cost	$ 397,756	$ 346,650
Accumulated depreciation and amortization	(189,849)	(169,821)
Property and equipment, net	207,907	176,829
Land [Member]
Property and equipment, cost	8,612	8,516
Building and Building Improvements [Member]
Property and equipment, cost	190,661	184,430
Machinery and Equipment [Member]
Property and equipment, cost	$ 198,483	$ 153,704

Note 3 - Supplemental Balance_6

Note 3 - Supplemental Balance Sheet and Cash Flow Information - Intangible Assets (Details) - USD ($) $ in Thousands		12 Months Ended
		Jun. 30, 2021	Jun. 30, 2020
Definite-lived intangibles assets		$ 941,535	$ 795,591
Accumulated amortization		(348,267)	(279,046)
Total		593,268	516,545
Total intangible assets, net		615,968	516,545
In Process Research and Development [Member]
In process research and development		$ 22,700	0
Minimum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)		1 year
Maximum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)		20 years
Developed Technology Rights [Member]
Definite-lived intangibles assets		$ 552,160	434,653
Developed Technology Rights [Member] | Minimum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)		9 years
Developed Technology Rights [Member] | Maximum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)		15 years
Trade Names [Member]
Definite-lived intangibles assets		$ 147,640	146,713
Trade Names [Member] | Minimum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)		2 years
Trade Names [Member] | Maximum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)		20 years
Customer Relationships [Member]
Definite-lived intangibles assets		$ 232,493	211,750
Customer Relationships [Member] | Minimum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)		7 years
Customer Relationships [Member] | Maximum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)		16 years
Patents [Member]
Finite-Lived Intangible Asset, Useful Life (Year)		10 years
Definite-lived intangibles assets		$ 2,926	2,475
Other Intangible Assets [Member]
Definite-lived intangibles assets	[1]	$ 6,316	$ 0
Other Intangible Assets [Member] | Minimum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	[1]	5 years
Other Intangible Assets [Member] | Maximum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	[1]	15 years
[1]	Increase in other intangibles assets is primarily due to $5.0 million recognized in intangible assets in the first quarter of fiscal 2021 for certain third party patented technology acquired.

Note 3 - Supplemental Balance_7

Note 3 - Supplemental Balance Sheet and Cash Flow Information - Changes to Carrying Amount of Net Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Beginning balance	$ 516,545	$ 579,429
Finite-lived Intangible Assets Acquired	153,311	0
Other additions	5,912	311
Amortization expense	(64,940)	(61,095)
Currency translation	5,140	(2,100)
Ending balance	$ 615,968	$ 516,545

Note 3 - Supplemental Balance_8

Note 3 - Supplemental Balance Sheet and Cash Flow Information - Estimated Future Amortization Expense for Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Jun. 30, 2020
2022	$ 74,482
2023	72,649
2024	69,780
2025	66,523
2026	62,739
Thereafter	247,095
Total	$ 593,268	$ 516,545

Note 3 - Supplemental Balance_9

Note 3 - Supplemental Balance Sheet and Cash Flow Information - Changes in Carrying Amount of Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Balance	$ 728,308	$ 732,667
Acquisitions (Note 4)		(326)
Currency Translation	11,939	(4,031)
Acquisitions (Note 4)	102,818
Balance	843,067	728,308
Protein Sciences [Member]
Balance	373,081	377,407
Acquisitions (Note 4)		(326)
Currency Translation	11,788	(4,000)
Acquisitions (Note 4)	7,848
Balance	392,717	373,081
Diagnostics and Genomics [Member]
Balance	355,229	355,260
Acquisitions (Note 4)		0
Currency Translation	151	(31)
Acquisitions (Note 4)	94,970
Balance	$ 450,350	$ 355,229

Note 3 - Supplemental Balanc_10

Note 3 - Supplemental Balance Sheet and Cash Flow Information - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands		12 Months Ended
		Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Income taxes paid		$ 20,952	$ 41,992	$ 36,814
Interest paid		13,576	18,615	21,497
Acquisition-related liabilities	[1]	23,600	(2,105)	12,600
Other intangibles	[2]	$ 4,000	$ 0	$ 0
[1]	Consists of holdback payments due at future dates and liabilities for contingent consideration. Amounts disclosed above represent the total non-cash change in the liability from the prior fiscal year. Further information regarding liabilities for contingent consideration can be found in Notes 4 and 5.
[2]	$4.0 million of the third party patented technology acquired in fiscal 2021 was a non-cash activity within the consolidated statement of cash flows as a cash payment was not made within the fiscal year ended June 30, 2021.

Note 4 - Acquisitions (Details

Note 4 - Acquisitions (Details Textual) - USD ($) $ in Thousands	Apr. 06, 2021	Apr. 02, 2021	Oct. 20, 2020	Jun. 04, 2019	Aug. 01, 2018	Jul. 02, 2018	Jun. 30, 2021	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Payments to Acquire Businesses, Net of Cash Acquired, Total								$ 225,352	$ 0	$ 289,492
Gain (Loss) on Escrow Settlement								0	7,170	$ 0
Changzhou Eminence Biotechnology [Member]
Business Acquisition, Percentage of Voting Interests Acquired			47.60%
Business Combination, Consideration Transferred, Total			$ 9,800
Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value			8,985				$ 8,985	8,985
Payments to Acquire Businesses, Gross		$ 6,000
Business Combination, Step Acquisition, Equity Interest in Acquiree, including Subsequent Acquisition, Percentage, Total		57.40%
Variable Interest Entity, Primary Beneficiary, Maximum Loss Exposure, Portion Stemming from Initial Investment							15,800	15,800
Goodwill, Purchase Accounting Adjustments							(963)
Payments to Acquire Businesses, Net of Cash Acquired, Total			$ 9,765				9,765
Changzhou Eminence Biotechnology [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Asset, Useful Life (Year)			13 years
Changzhou Eminence Biotechnology [Member] | Customer Relationships [Member]
Finite-Lived Intangible Asset, Useful Life (Year)			10 years
Acquisition of Asuragen, Inc. [Member]
Business Combination, Consideration Transferred, Total	$ 233,887
Payments to Acquire Businesses, Net of Cash Acquired, Total	215,587
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	105,000						105,000	105,000
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual	7,100
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual	$ (3,400)
Acquisition of Asuragen, Inc. [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	14 years
Acquisition of Asuragen, Inc. [Member] | Customer Relationships [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	16 years
Acquisition of Asuragen, Inc. [Member] | Trade Names [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	5 years
Acquisition of Asuragen, Inc. [Member] | Noncompete Agreements [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	3 years
QT Holdings Corporation [Member]
Payments to Acquire Businesses, Net of Cash Acquired, Total						$ 20,500			20,462
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High						$ 51,000	51,000	51,000
QT Holdings Corporation [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Asset, Useful Life (Year)						14 years
Exosome Diagnostics, Inc [Member]
Payments to Acquire Businesses, Net of Cash Acquired, Total					$ 251,600				251,623
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High					325,000
Gain (Loss) on Escrow Settlement					$ 7,200
Exosome Diagnostics, Inc [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Asset, Useful Life (Year)					15 years
Exosome Diagnostics, Inc [Member] | Trade Names [Member]
Finite-Lived Intangible Asset, Useful Life (Year)					15 years
B-MoGen [Member]
Goodwill, Purchase Accounting Adjustments									300
Finite-Lived Intangible Asset, Useful Life (Year)					14 years
Payments to Acquire Businesses, Net of Cash Acquired, Total				$ 17,500					$ 17,448
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High				38,000			$ 38,000	$ 38,000
Business Combination, Step Acquisition, Equity Interest in Acquiree, Before Remeasurement to Fair Value				1,400
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain				$ 3,700
B-MoGen [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Asset, Useful Life (Year)				14 years

Note 4 - Acquisitions - Prelimi

Note 4 - Acquisitions - Preliminary and Final Fair Value of Assets and Liabilities Assumed (Details) - USD ($) $ in Thousands	Apr. 06, 2021	Oct. 20, 2020	Jun. 04, 2019	Aug. 01, 2018	Jul. 02, 2018	Jun. 30, 2021	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Goodwill						$ 843,067	$ 843,067	$ 728,308	$ 732,667
Payments to Acquire Businesses, Net of Cash Acquired, Total							225,352	0	$ 289,492
Changzhou Eminence Biotechnology [Member]
Current assets, net of cash		$ 3,145				3,145	3,145
Equipment and other long-term assets		1,639				1,639	1,639
Goodwill		8,811				7,848	7,848
Goodwill, Purchase Accounting Adjustments						(963)
Total assets acquired		22,506				21,543	21,543
Total assets acquired, adjustments						(963)
Liabilities		1,436				1,436	1,436
Deferred income taxes, net		2,320				1,357	1,357
Deferred income taxes, net, adjustments						(963)
Net assets acquired		18,750				18,750	18,750
Payments to Acquire Businesses, Net of Cash Acquired, Total		9,765				9,765
Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value		8,985				8,985	8,985
Net assets acquired		18,750				18,750
Net assets acquired		9,800
Changzhou Eminence Biotechnology [Member] | Developed Technology Rights [Member]
Intangible assets		6,778				6,778	6,778
Changzhou Eminence Biotechnology [Member] | Customer Relationships [Member]
Intangible assets		$ 2,133				$ 2,133	$ 2,133
Acquisition of Asuragen, Inc. [Member]
Current assets, net of cash	$ 10,422
Equipment and other long-term assets	3,762
Goodwill	94,970
Total assets acquired	253,554
Liabilities	4,003
Deferred income taxes, net	15,664
Net assets acquired	233,887
Payments to Acquire Businesses, Net of Cash Acquired, Total	215,587
Contingent consideration payable	18,300
Net assets acquired	233,887
Acquisition of Asuragen, Inc. [Member] | In Process Research and Development [Member]
In-process research and development	22,700
Acquisition of Asuragen, Inc. [Member] | Developed Technology Rights [Member]
Intangible assets	107,000
Acquisition of Asuragen, Inc. [Member] | Customer Relationships [Member]
Intangible assets	11,700
Acquisition of Asuragen, Inc. [Member] | Trade Names [Member]
Intangible assets	2,000
Acquisition of Asuragen, Inc. [Member] | Noncompete Agreements [Member]
Intangible assets	$ 1,000
B-MoGen [Member]
Current assets, net of cash								504
Equipment and other long-term assets								269
Goodwill								16,131
Goodwill, Purchase Accounting Adjustments								300
Total assets acquired								31,304
Liabilities								211
Deferred income taxes, net								3,051
Net assets acquired								28,042
Payments to Acquire Businesses, Net of Cash Acquired, Total			$ 17,500					17,448
Net assets acquired								28,042
Contingent consideration payable								10,594
B-MoGen [Member] | Developed Technology Rights [Member]
Intangible assets								14,000
B-MoGen [Member] | Customer Relationships [Member]
Intangible assets								400
Exosome Diagnostics, Inc [Member]
Current assets, net of cash								2,611
Equipment and other long-term assets								2,212
Goodwill								105,362
Total assets acquired								275,485
Liabilities								3,716
Deferred income taxes, net								16,346
Net assets acquired								255,423
Payments to Acquire Businesses, Net of Cash Acquired, Total				$ 251,600				251,623
Net assets acquired								255,423
Contingent consideration payable								3,800
Exosome Diagnostics, Inc [Member] | Developed Technology Rights [Member]
Intangible assets								105,000
Exosome Diagnostics, Inc [Member] | Customer Relationships [Member]
Intangible assets								2,300
Exosome Diagnostics, Inc [Member] | Trade Names [Member]
Intangible assets								58,000
QT Holdings Corporation [Member]
Current assets, net of cash								36
Equipment and other long-term assets								228
Goodwill								14,481
Total assets acquired								27,001
Liabilities								296
Deferred income taxes, net								943
Net assets acquired								25,762
Payments to Acquire Businesses, Net of Cash Acquired, Total					$ 20,500			20,462
Net assets acquired								25,762
Contingent consideration payable								5,300
QT Holdings Corporation [Member] | Developed Technology Rights [Member]
Intangible assets								$ 12,256

Note 5 - Fair Value Measureme_3

Note 5 - Fair Value Measurements (Details Textual) - USD ($) $ in Thousands	1 Months Ended			12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019	May 31, 2021	Apr. 06, 2021	Dec. 31, 2020	Jun. 04, 2019	Oct. 31, 2018	Jul. 02, 2018
Interest Expense, Total				$ 13,952	$ 19,197	$ 21,705
Nonoperating Income (Expense), Total				(89,121)	119,058	(34,704)
Income Tax Expense (Benefit), Total				8,590	47,181	$ 15,943
Business Combination, Contingent Consideration, Liability, Total				29,400
Acquisition of Asuragen, Inc. [Member]
Business Combination, Contingent Consideration, Liability, Total				18,300
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High				105,000				$ 105,000
QT Holdings Corporation [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High				51,000								$ 51,000
B-MoGen [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High				38,000						$ 38,000
Reclassification out of Accumulated Other Comprehensive Income [Member] | AOCI Attributable to Parent [Member]
Interest Expense, Total				8,598
Nonoperating Income (Expense), Total				512
Designated as Hedging Instrument [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | AOCI Attributable to Parent [Member]
Interest Expense, Total				8,600	3,500
Nonoperating Income (Expense), Total				(500)
Income Tax Expense (Benefit), Total				(2,100)
Forward Starting Swap [Member] | Other Current Liabilities [Member] | Not Designated as Hedging Instrument [Member]
Derivative Liability, Current				800
Forward Starting Swap [Member] | Cash Flow Hedging [Member]
Derivative, Notional Amount											$ 380,000
Derivative Notional Amount, Decrease in Period			$ 100,000
Forward Starting Swap [Member] | Cash Flow Hedging [Member] | Other Noncurrent Liabilities [Member]
Derivative Notional Amount, Dedesignated					80,000				$ 80,000
Hedging Liabilities, Noncurrent				7,600
Forward Starting Swap [Member] | Cash Flow Hedging [Member] | Forecast [Member]
Derivative Notional Amount, Decrease in Period	$ 200,000	$ 80,000
New Forward Starting Swap [Member] | Cash Flow Hedging [Member]
Derivative, Notional Amount							$ 200,000
New Forward Starting Swap [Member] | Cash Flow Hedging [Member] | Other Noncurrent Assets [Member]
Hedging Assets, Noncurrent, Total				300
CCXI [Member]
Investments, Total				6,600	6,600
Investments, Fair Value Disclosure, Total				$ 1,400	$ 8,000

Note 5 - Fair Value Measureme_4

Note 5 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) - USD ($) $ in Thousands		Jun. 30, 2021	Jun. 30, 2020
Business Combination, Contingent Consideration, Liability, Total		$ 29,400
Fair Value, Recurring [Member]
Derivative instruments - cash flow hedges		275
Total Assets		32,738	$ 124,268
Business Combination, Contingent Consideration, Liability, Total		29,400	6,137
Derivative instruments - cash flow hedges		8,376	17,331
Total Liabilities		37,776	23,468
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Derivative instruments - cash flow hedges		0
Total Assets		31,081	116,272
Business Combination, Contingent Consideration, Liability, Total		0
Derivative instruments - cash flow hedges		0
Total Liabilities		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Derivative instruments - cash flow hedges		275
Total Assets		1,657	0
Business Combination, Contingent Consideration, Liability, Total		0
Derivative instruments - cash flow hedges		8,376	0
Total Liabilities		8,376	6,137
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Derivative instruments - cash flow hedges		0
Total Assets		0
Business Combination, Contingent Consideration, Liability, Total		29,400
Derivative instruments - cash flow hedges		0
Total Liabilities		29,400
Equity Securities [Member] | Fair Value, Recurring [Member]
Investments, Fair Value Disclosure	[1]	19,963	87,842
Equity Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Investments, Fair Value Disclosure	[1]	18,581	79,846
Equity Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Investments, Fair Value Disclosure	[1]	1,382	0
Equity Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Investments, Fair Value Disclosure	[1]	0
Certificates of Deposit [Member] | Fair Value, Recurring [Member]
Investments, Fair Value Disclosure	[2]	12,500	36,426
Certificates of Deposit [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Investments, Fair Value Disclosure	[2]	12,500	$ 36,426
Certificates of Deposit [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Investments, Fair Value Disclosure	[2]	0
Certificates of Deposit [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Investments, Fair Value Disclosure	[2]	$ 0
[1]	Included in available-for-sale investments on the balance sheet. The cost basis in the Company's investment in CCXI at June 30, 2021 and June 30, 2020 was $6.6 million and $6.6 million respectively. The Company has a warrant to purchase additional CCXI equity shares which was valued at $1.4 million as of June 30, 2021. The fair value of the warrant as of June 30, 2020 was $8.0 million
[2]	Included in available-for-sale investments on the balance sheet. The certificate of deposits have contractual maturity dates within one year.

Note 5 - Fair Value Measureme_5

Note 5 - Fair Value Measurements - Liability Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Details) - Contingent Consideration [Member] - Fair Value, Inputs, Level 3 [Member] - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Fair value at the beginning of period	$ 6,137	$ 12,600
Purchase price contingent consideration (Note 4)	18,300	0
Payments	(337)	(4,358)
Gain on escrow settlement	0	(1,200)
Change in fair value of contingent consideration	5,300	(905)
Contingent consideration payable	$ 29,400	$ 6,137

Note 6 - Debt and Other Finan_2

Note 6 - Debt and Other Financing Arrangements (Details Textual) - USD ($) $ in Millions	Aug. 01, 2018	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Proceeds from Long-term Lines of Credit		$ 256	$ 40	$ 580
Credit Agreement [Member]
Long-term Debt, Total		$ 341	$ 357
Credit Agreement [Member] | Term Loan [Member]
Debt Instrument, Face Amount	$ 250
Proceeds from Issuance of Long-term Debt, Total	250
Revolving Credit Facility [Member] | Credit Agreement [Member]
Line of Credit Facility, Maximum Borrowing Capacity	600
Line of Credit Facility, Additional Borrowing Capacity	$ 200
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.125%
Line of Credit, Current	$ 12.5
Proceeds from Long-term Lines of Credit	$ 330

Note 7 - Leases (Details Textua

Note 7 - Leases (Details Textual) $ in Millions	12 Months Ended
	Jun. 30, 2021USD ($)ft²
Variable Lease, Cost	$ 3.6
Fixed Lease, Cost	$ 32.5
Lessee, Operating Lease, Lease Not yet Commenced, Area of Property (Square Foot) | ft²	25,000
Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract (Year)	25 years
Lessee, Operating Lease, Lease Not yet Commenced, Annunal Rental Impact	$ 0.3
Maximum [Member]
Lessee, Operating Lease, Renewal Term (Year)	5 years

Note 7 - Leases - Balance Sheet

Note 7 - Leases - Balance Sheet Classification (Details) - USD ($) $ in Thousands	Jun. 30, 2021		Jun. 30, 2020
Operating Lease, Right-of-Use Asset	$ 73,834	[1]	$ 71,465
Current operating lease liabilities	11,602	[1]	9,535
Noncurrent operating lease liabilities	67,625	[1]	$ 67,248
Total operating lease liabilities	$ 79,227
Weighted average remaining lease term (in years): (Year)	7 years 11 months 19 days
Weighted average discount rate:	3.93%
[1]	The right of use asset, current operating lease liabilities, and noncurrent lease liabilities on the Consolidated Balance Sheet exclude a definitive agreement entered into by the Company in June 2021 for a 25,000 square foot facility in Dublin, Ireland for the next 25 years with annual rental impact of $0.3 million. The lease will commence during fiscal 2022 after construction is completed by the landlord. As the lease has not commenced as of June 30, 2021, the related asset and liability were not recorded.

Note 7 - Leases - Cash Paid (De

Note 7 - Leases - Cash Paid (Details) $ in Thousands	12 Months Ended
	Jun. 30, 2021USD ($)
Cash amounts paid on operating lease liabilities	$ 13,492	[1]
Right of use assets obtained in exchange for lease liabilities	$ 12,144
[1]	Total cash paid for the Company's operating leases during the year ended June 30, 2021 include cash amounts paid on operating lease liabilities and variable lease expenses. Cash flow impacts from right of use assets and lease liabilities are presented net on the cash flow statement in changes in other operating activity.

Note 7 - Leases - Fair Value of

Note 7 - Leases - Fair Value of the Lease Liability by Payment Date (Details) $ in Thousands	Jun. 30, 2021USD ($)
2022	$ 14,349
2023	13,371
2024	11,840
2025	10,780
2026	10,120
Thereafter	32,331
Total	92,791
Less: Amounts representing interest	13,564
Total lease obligations	$ 79,227

Note 8 - Supplemental Equity _3

Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Common Stock, Dividends, Per Share, Declared (in dollars per share)	$ 1.28	$ 1.28	$ 1.28
Stock Repurchased During Period, Shares (in shares)	120,000	279,381
Stock Repurchased During Period, Average Share Price (in dollars per share)	$ 359.81	$ 179.37
Interest Expense, Total	$ 13,952	$ 19,197	$ 21,705
Nonoperating Income (Expense), Total	(89,121)	119,058	(34,704)
Deferred Income Tax Expense (Benefit), Total	(28,013)	13,607	$ (14,021)
Changzhou Eminence Biotechnology [Member]
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Noncontrolling Interest	103
AOCI Attributable to Parent [Member]
Deferred Income Tax Expense (Benefit), Total	(1,908)	$ (4,058)
Reclassification out of Accumulated Other Comprehensive Income [Member] | AOCI Attributable to Parent [Member]
Interest Expense, Total	8,598
Nonoperating Income (Expense), Total	512
Reclassification from AOCI, Current Period, Tax, Total	$ 2,150

Note 8 - Supplemental Equity _4

Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details) - USD ($) $ in Thousands		12 Months Ended
		Jun. 30, 2021		Jun. 30, 2020	Jun. 30, 2019
Balance		$ 1,381,192
Balance		1,562,971		$ 1,381,192
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]
Balance		0		0	$ 24,682
Other comprehensive income (loss) before reclassifications		0	[1]	0	0
Reclassification from loss on derivatives to interest expense, net of taxes	[2]	0		0
Balance		0		0	0
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member] | Accounting Standards Update 2018-02 [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member]
Balance					2,371
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member] | Accounting Standards Update 2016-01 [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member]
Balance					(27,053)
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]
Balance		(83,946)		(73,983)	(69,496)
Other comprehensive income (loss) before reclassifications		32,848	[1]	(9,963)	(4,487)
Reclassification from loss on derivatives to interest expense, net of taxes	[2]	0		0
Balance		(51,098)		(83,946)	(73,983)
Accumulated Foreign Currency Adjustment Attributable to Parent [Member] | Accounting Standards Update 2018-02 [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member]
Balance					0
Accumulated Foreign Currency Adjustment Attributable to Parent [Member] | Accounting Standards Update 2016-01 [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member]
Balance					0
Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]
Balance		(13,253)		(9,537)	0
Other comprehensive income (loss) before reclassifications		100	[1]	(7,179)	(9,537)
Reclassification from loss on derivatives to interest expense, net of taxes	[2]	6,960		3,464
Balance		(6,193)		(13,253)	(9,537)
Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member] | Accounting Standards Update 2018-02 [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member]
Balance					0
Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member] | Accounting Standards Update 2016-01 [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member]
Balance					0
AOCI Attributable to Parent [Member]
Balance		(97,199)		(83,521)	(44,814)
Other comprehensive income (loss) before reclassifications		32,948	[1]	(17,142)	(14,024)
Reclassification from loss on derivatives to interest expense, net of taxes	[2]	6,960		3,464
Balance		$ (57,291)		$ (97,199)	(83,521)
AOCI Attributable to Parent [Member] | Accounting Standards Update 2018-02 [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member]
Balance					2,371
AOCI Attributable to Parent [Member] | Accounting Standards Update 2016-01 [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member]
Balance					$ (27,053)
[1]	Other comprehensive income related to foreign currency translation adjustments in the table above includes the amount attributable to Bio-Techne and excludes the $103 attributable to the non-controlling interest in Eminence.
[2]	Gains (losses) on the interest swap will be reclassified into interest expense as payments on the derivative agreement are made. The Company reclassified $8,598 to interest expense and $512 to non-operating income relating to variable interest payments that were probable not to occur as further discussed in Note 5 for the fiscal year ended June 30, 2021. The Company also recorded a related tax benefit of $2,150 during fiscal 2021. The Company had deferred tax benefits of $1,908 and $4,058 included in the accumulated other comprehensive income loss as of June 30, 2021 and June 30, 2020, respectively.

Note 9 - Earnings Per Share (De

Note 9 - Earnings Per Share (Details Textual) - shares shares in Millions	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	0.6	0.9	1.3

Note 9 - Earnings Per Share - S

Note 9 - Earnings Per Share - Shares Used in the Earnings Per Share Computations (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Net earnings	$ 139,585	$ 229,296	$ 96,072
Net earnings (loss) attributable to noncontrolling interest	(825)	0	0
Net income	140,410	229,296	96,072
Income allocated to participating securities	(86)	(224)	(105)
Income available to common shareholders	$ 140,324	$ 229,072	$ 95,967
Basic (in shares)	38,747	38,201	37,781
Basic (in dollars per share)	$ 3.62	$ 6	$ 2.54
Income allocated to participating securities	$ (86)	$ (224)	$ (105)
Income available to common shareholders	$ 140,324	$ 229,072	$ 95,967
Dilutive effect of stock options and restricted stock units (in shares)	1,736	1,200	1,111
Diluted (in shares)	40,483	39,401	38,892
Diluted (in dollars per share)	$ 3.47	$ 5.82	$ 2.47

Note 10 - Share-based Compens_3

Note 10 - Share-based Compensation and Other Benefit Plans (Details Textual) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	12 Months Ended
	Oct. 31, 2020	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2010	Oct. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)		3,717,000	3,609,000	3,656,000	3,452,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)		$ 59.75	$ 37.01	$ 34.66
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value		$ 145.6	$ 99.3	$ 159
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value		70.5	71.1	31.7
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total		$ 37.1
Share-based Compensation Arrangement by Share-based Payment Award, Non-vested, Forfeiture Rate		4.60%
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)		2 years 1 month 6 days
US Profit Sharing and Savings Plan [Member]
Defined Contribution Plan, Cost		$ 3.4	3.2	2.8
GB Profit Sharing and Savings Plan [Member]
Defined Contribution Plan, Cost		1.6	1.4	1.4
Selling, General and Administrative Expenses [Member]
Share-based Payment Arrangement, Expense		46.4	32.4	32.3
Cost of Sales [Member]
Share-based Payment Arrangement, Expense			1.6
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value		2.8	2.5	2.3
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value		$ 6.7	5.7	3.1
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)					3 years
Equity Incentive Plan 2010 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)						7,500,000
The 2020 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)	2,484,202
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)	1,300,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)		1,100,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)		3,700,000
The 2020 Equity Incentive Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)						10 years
Employee Stock Purchase Plan 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)							200,000
Share-based Payment Arrangement, Expense		$ 0.9	0.4	0.5
Performance Incentive Programs [Member] | Executive Officer [Member]
Salary and Wage, Officer, Excluding Cost of Good and Service Sold		$ 21.1	$ 10.5	$ 9.3
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total (in shares)		762,761	751,499	618,898
Performance Incentive Programs [Member] | Restricted Stock [Member] | Executive Officer [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in shares)		11,803	15,398	11,279
Performance Incentive Programs [Member] | Restricted Stock Units (RSUs) [Member] | Executive Officer [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in shares)		30,823	30,858	25,903

Note 10 - Share-based Compens_4

Note 10 - Share-based Compensation and Other Benefit Plans - Assumptions Used in Black-Scholes Option-Pricing Model (Details)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Dividend yield	0.24%	0.67%	0.74%
Expected lives (years) (Year)	4 years 4 months 24 days	4 years	4 years 1 month 6 days
Minimum [Member]
Expected volatility	25.00%	22.00%	20.00%
Risk-free interest rates	0.20%	1.30%	2.50%
Maximum [Member]
Expected volatility	30.00%	24.00%	23.00%
Risk-free interest rates	0.70%	1.90%	3.00%

Note 10 - Share-based Compens_5

Note 10 - Share-based Compensation and Other Benefit Plans - Stock Option Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Outstanding, shares (in shares)	3,609	3,656	3,452
Outstanding, weighted average exercise price (in dollars per share)	$ 140.28	$ 121.16	$ 105.17
Granted, shares (in shares)	763	752	917
Granted, weighted average exercise price (in dollars per share)	$ 277.75	$ 190.80	$ 173.89
Forfeited, shares (in shares)	(28)	(56)	(330)
Forfeited, weighted average exercise price (in dollars per share)	$ 214.33	$ 95.97	$ 129.93
Exercised, shares (in shares)	(627)	(743)	(383)
Exercised, weighted average exercise price (in dollars per share)	$ 112.53	$ 157.45	$ 95.29
Outstanding, shares (in shares)	3,717	3,609	3,656
Outstanding, weighted average exercise price (in dollars per share)	$ 172.63	$ 140.28	$ 121.16
Outstanding, aggregate intrinsic value	$ 1,031.9
Outstanding, weighted average contractual life (Year)	4 years 1 month 6 days
Exercisable, shares (in shares)	1,764	1,564	1,467
Exercisable, weighted average exercise price (in dollars per share)	$ 126.44	$ 112.60	$ 98.70
Exercisable, aggregate intrinsic value	$ 571.3
Exercisable, weighted average contractual life (Year)	3 years

Note 10 - Share-based Compens_6

Note 10 - Share-based Compensation and Other Benefit Plans - Restricted Stock and Restricted Stock Units Activity (Details) - $ / shares shares in Thousands	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Restricted Stock [Member]
Balance, shares (in shares)	28	30	35
Balance, weighted average exercise price (in dollars per share)	$ 177.20	$ 147.94	$ 117.39
Granted, shares (in shares)	12	15	15
Granted, weighted average exercise price (in dollars per share)	$ 264.73	$ 193.48	$ 177.93
Vested, shares (in shares)	(17)	(18)	(20)
Vested, weighted average exercise price (in dollars per share)	$ 171.64	$ 142.12	$ 116.76
Forfeited, shares (in shares)	0	0	0
Forfeited, weighted average exercise price (in dollars per share)	$ 0	$ 0	$ 0
Balance, weighted average contractual life (Year)	6 years 25 days
Balance, shares (in shares)	23	28	30
Balance, weighted average exercise price (in dollars per share)	$ 226.07	$ 177.20	$ 147.94
Restricted Stock Units (RSUs) [Member]
Balance, shares (in shares)	116	139	148
Balance, weighted average exercise price (in dollars per share)	$ 159.25	$ 134.17	$ 117.95
Granted, shares (in shares)	31	31	56
Granted, weighted average exercise price (in dollars per share)	$ 300.78	$ 192.08	$ 170.96
Vested, shares (in shares)	(51)	(51)	(28)
Vested, weighted average exercise price (in dollars per share)	$ 130.18	$ 111.07	$ 110.86
Forfeited, shares (in shares)	0	(3)	(36)
Forfeited, weighted average exercise price (in dollars per share)	$ 0	$ 155.60	$ 143.72
Balance, weighted average contractual life (Year)	5 years 4 months 9 days
Balance, shares (in shares)	96	116	139
Balance, weighted average exercise price (in dollars per share)	$ 220.53	$ 159.25	$ 134.17

Note 11 - Income Taxes (Details

Note 11 - Income Taxes (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Effective Income Tax Rate Reconciliation, Percent, Total	5.80%	17.10%	14.20%
Income Tax Expense (Benefit), Discrete Tax Items	$ 28,100	$ 19,400	$ 12,700
Excess Tax Benefit from Share-based Compensation, Operating Activities	28,100	17,700	7,200
Income Tax Expense (Benefit), Discrete Tax Items, Acquisitions			(3,200)
Income Tax Expense (Benefit) Discrete Tax Items State Apportionments			$ (2,000)
Deferred Tax Assets, Valuation Allowance, Total	6,665	7,523
Deferred Tax Assets, Net of Valuation Allowance, Total	86,883	$ 73,353
Undistributed Earnings of Foreign Subsidiaries	223,000
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	5,200
Decrease in Unrecognized Tax Benefits is Reasonably Possible	2,600
Operating Loss Carryforwards [Member]
Deferred Tax Assets, Net of Valuation Allowance, Total	26,600
Tax Credit Carryforwards [Member]
Deferred Tax Assets, Net of Valuation Allowance, Total	12,600
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Operating Loss Carryforwards, Total	92,100
Tax Credit Carryforward, Amount	10,100
State and Local Jurisdiction [Member]
Operating Loss Carryforwards, Total	129,600
Tax Credit Carryforward, Amount	4,400
Foreign Tax Authority [Member]
Operating Loss Carryforwards, Total	$ 13,900

Note 11 - Income Taxes - Compon

Note 11 - Income Taxes - Components of Provision for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Domestic	$ 95,662	$ 245,365	$ 64,081
Foreign	52,513	31,112	47,934
Earnings before income taxes	148,175	276,477	112,015
Federal	15,179	18,976	16,090
State	6,681	6,018	544
Foreign	14,743	8,580	13,329
Total current tax provision	36,603	33,574	29,963
Federal	(20,812)	14,074	(6,903)
State	(4,962)	2,055	(3,977)
Foreign	(2,239)	(2,522)	(3,142)
Total deferred tax provision	(28,013)	13,607	(14,021)
Total income tax provision	$ 8,590	$ 47,181	$ 15,943

Note 11 - Income Taxes - Reconc

Note 11 - Income Taxes - Reconciliation of Federal Tax Calculated at Statutory Rate (Details)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Income tax expense at federal statutory rate	21.00%	21.00%	21.00%
State income taxes, net of federal benefit	0.60%	2.30%	(1.50%)
Research and development tax credit	(1.80%)	(0.70%)	(1.60%)
Contingent consideration adjustment	0.80%	(0.20%)	(0.40%)
Foreign tax rate differences	0.80%	(0.20%)	0.20%
Option exercises	(16.90%)	(5.70%)	(5.80%)
U.S. taxation of foreign earnings	(0.10%)	0.90%	3.70%
Foreign derived intangible income	(5.10%)	(0.90%)	(2.00%)
Executive compensation limitations	6.50%	1.60%	0.40%
Other, net	0.00%	(1.00%)	0.20%
Effective tax rate	5.80%	17.10%	14.20%

Note 11 - Income Taxes - Tempor

Note 11 - Income Taxes - Temporary Differences Comprising Deferred Taxes on Consolidated Balance Sheets (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Jun. 30, 2020
Inventory	$ 6,730	$ 7,769
Net operating loss carryovers	31,345	25,707
Tax credit carryovers	14,486	9,568
Excess tax basis in equity investments	2,429	2,423
Deferred compensation	11,108	10,755
Derivative - cash flow hedge	1,908	4,058
Lease liability	17,016	16,256
Other	8,526	4,340
Valuation allowance	(6,665)	(7,523)
Deferred tax assets	86,883	73,353
Net unrealized gain on available-for-sale investments	(3,159)	(19,102)
Intangible asset amortization	(150,765)	(128,279)
Depreciation	(9,099)	(10,764)
Right of use asset	15,868	15,118
Other	1,117	1,180
Deferred tax liabilities	(180,008)	(174,443)
Net deferred tax liabilities	$ (93,125)	$ (101,090)

Note 11 - Income Taxes - Reco_2

Note 11 - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Balance	$ 4,297	$ 5,032	$ 1,947
Additions due to acquisitions	0	0	900
Additions for tax positions of prior year	4,038	306	2,185
Decrease in unrecognized tax benefits for prior year positions	(778)	(1,041)	0
Settlements	(286)	0	0
Ending balances	$ 7,271	$ 4,297	$ 5,032

Note 12 - Segment Information_2

Note 12 - Segment Information (Details Textual)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Number of Reportable Segments	2
Customer Concentration Risk [Member] | Revenue, Segment Benchmark [Member] | Protein Sciences [Member]
Number of Major Customers	0	0	0
Customer Concentration Risk [Member] | Revenue, Segment Benchmark [Member] | Diagnostics and Genomics [Member]
Number of Major Customers	0	0	0

Note 12 - Segment Information -

Note 12 - Segment Information - Financial Information Relating to Reportable Segments (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Revenues, net	$ 931,032	$ 738,691	$ 714,006
Operating income	237,296	157,419	146,719
Costs recognized upon sale of acquired inventory	(1,565)	0	(3,739)
Gain on escrow settlement	0	7,170	0
Corporate general, selling and administrative expenses	(324,951)	(260,583)	(264,359)
Total long-lived assets	207,907	176,829
Total intangible assets	615,968	516,545	579,429
United States and Canada [Member]
Total long-lived assets	190,501	162,039
Total intangible assets	594,512	499,875
Europe [Member]
Total long-lived assets	13,949	13,120
Total intangible assets	9,369	12,349
Asia [Member]
Total long-lived assets	3,457	1,670
Total intangible assets	12,087	4,321
Consumables [Member]
Revenues, net	751,985	602,642	588,979
Protein Sciences [Member] | Consumables [Member]
Revenues, net	557,037	431,052	430,655
Diagnostics and Genomics [Member] | Consumables [Member]
Revenues, net	194,948	171,590	158,324
Operating Segments [Member]
Operating income	367,262	249,894	250,998
Costs recognized upon sale of acquired inventory	(1,565)	0	(3,739)
Amortization of acquired intangible assets	(64,239)	(60,865)	(58,550)
Gain on escrow settlement	0	7,169	0
Acquisition related expenses	(7,114)	(416)	(2,282)
Restructuring costs	(142)	(87)	0
Stock-based compensation, inclusive of employer taxes	(51,846)	(34,262)	(33,057)
Operating Segments [Member] | Protein Sciences [Member]
Revenues, net	704,564	555,352	543,159
Operating income	328,837	234,929	240,919
Operating Segments [Member] | Diagnostics and Genomics [Member]
Revenues, net	227,744	184,549	171,674
Operating income	38,425	14,965	10,079
Intersegment Eliminations [Member]
Revenues, net	(1,276)	(1,210)	(827)
Corporate, Non-Segment [Member]
Corporate general, selling and administrative expenses	$ (5,060)	$ (4,015)	$ (6,651)